27.1. Overview {#s0005}
==============

Since the identification of its pathogenic features by Alois Alzheimer in 1906, more than 90,000 papers have been published on Alzheimer's disease (AD) to date (2.5 million references on cancer since 1818; 1.6 million on cardiovascular disorders since 1927; and 1.01 million on central nervous system disorders since 1893) [@b0005]. The number of people affected by dementia is becoming a public and socioeconomic concern in many countries all over the world, independent of economic conditions. The growth of the elderly population is a common phenomenon in both developed and developing countries, bringing about future challenges in terms of health policy and disability rates.

In the United States, rates for the leading causes of death are heart disease (200.2 per 100,000), cancer (180.7 per 100,000), and stroke (43.6 per 100,000). AD is the fifth leading cause of death in people older than 65 years of age, representing 71,600 deaths per year. AD affects approximately 5.4 million individuals in the United States and is estimated to affect up to 16 million by 2050 [@b0010]. Disability caused by senility and dementia affects 9.2 per 1000 in the population aged 65--74 years, 33.5 per 1000 in those within the 75--84 range, and 83.4 per 1000 in the population over 85 years [@b0015], [@b0020]. In low- to middle-income countries, dementia makes the largest contribution to disability, with a median population-attributable prevalence fraction of 25.1%, followed by stroke (11.4%), limb impairment (10.5%), arthritis (9.9%), depression (8.3%), eyesight problems (6.8%), and gastrointestinal impairments (6.5%) [@b0025].

In Western countries, AD is the most prevalent form of dementia (45--60%), followed by vascular dementia (30--40%), and mixed dementia (10--20%), which in people older than 85 years of age may account for more than 80% of cases.

The different forms of dementia pose several challenges to society and to the scientific community: (1) they represent an epidemiological problem and a socioeconomic, psychological, and family burden; (2) most of them have an obscure/complex pathogenesis; (3) their diagnosis is not easy and lacks specific biomarkers; and (4) their treatment is difficult and inefficient.

In terms of economic burden, approximately 10--20% of direct costs are associated with pharmacological treatment, with a gradual increase that parallels the severity of the disease. A Canadian study [@b0030] shows that the mean total cost to treat patients with very mild AD is \$367 per month, compared with \$4063 per month for patients with severe or very severe AD. Only 20--30% of patients with dementia respond appropriately to conventional drugs, and the onset of adverse drug reactions imposes the need for other drugs to neutralize side effects, thus multiplying the initial cost of the pharmacological treatment and the health risk for the patients [@b0035]. Wimo et al. [@b0040] studied the economic impact of dementia in Europe in the EU-funded Eurocode project and found that the total cost of dementia in EU27 countries in 2008 was estimated to be €160 billion (€22,000 per dementia patient per year), of which 56% were costs of informal care. The corresponding costs for the whole of Europe were €177 billion. Informal caregiver costs were the largest cost component, accounting for about half to just over 60% of total societal costs, depending on the country and AD severity [@b0045].

In addition (and related) to the problem of direct and indirect costs for the management of dementia, there is an alarming abuse of inappropriate psychotropic drug consumption worldwide. Antipsychotic medications are taken by more than 30% of elderly patients with dementia [@b0050], and conventional antipsychotics are associated with a higher risk of all-cause mortality among nursing home residents [@b0055].

Abuse, misuse, self-prescription, and uncontrolled medical prescription of CNS drugs are becoming major problems with unpredictable consequences for brain health. The pharmacological management of dementia is an issue of special concern because of the polymedication required to modulate its symptomatic complexity where cognitive decline, behavioral changes, and psychomotor deterioration coexist. In parallel, a growing body of fresh knowledge is emerging on the pathogenesis of dementia, together with data on the neurogenomics and pharmacogenomics of CNS disorders. The incorporation of this new armamentarium of molecular pathology and genomic medicine into daily medical practice, together with educational programs for the correct use of drugs, must help researchers and clinicians to (1) understand AD pathogenesis; (2) establish an early diagnosis; and (3) optimize therapeutics either as a preventive strategy or as formal symptomatic treatment [@b0035], [@b0060].

27.2. Toward a Personalized Medicine for Dementia and Neurodegenerative Disorders {#s0010}
=================================================================================

Common features of neurodegenerative disorders include the following:•Polygenic/complex disorders in which genetic, epigenetic, and environmental factors are involved•Deterioration of higher activities of the CNS•Multifactorial dysfunction in several brain circuits•Accumulation of toxic proteins in the nervous tissue

For instance, the neuropathological hallmarks of AD (amyloid deposition in senile plaques, neurofibrillary tangle formation, and neuronal loss) are merely the phenotypic expression of a pathogenic process in which different gene clusters and their products are potentially involved [@b0035], [@b0060].

A large number of the genes that form the structural architecture of the human genome are expressed in the brain in a time-dependent manner along the lifespan. The cellular complexity of the CNS (10^3^ different cell types) and synapses (each of the 10^11^ neurons in the brain having around 10^3^--10^4^ synapses with a complex multiprotein structure integrated by 10^3^ different proteins) requires very powerful technology for gene expression profiling, which is still in its very early stages and is not devoid of technical obstacles and limitations [@b0065]. Transcripts of 16,896 genes have been measured in different CNS regions. Each region possesses its own unique transcriptome fingerprint that is independent of age, gender, and energy intake. Fewer than 10% of genes are affected by age, diet, or gender, with most of these changes occurring between middle and old age. Gender and energy restriction have robust influences on the hippocampal transcriptome of middle-aged animals. Prominent functional groups of age- and energy-sensitive genes are those encoding proteins involved in DNA damage responses, mitochondrial and proteasome functions, cell fate determination, and synaptic vesicle trafficking [@b0070].

The introduction of novel procedures in an integral genomic medicine protocol for CNS disorders and dementia is imperative in drug development and in clinical practice in order to improve diagnostic accuracy and to optimize therapeutics. Personalized strategies, adapted to the complexity of each case, are essential to depict a clinical profile based on specific biomarkers correlating with individual genomic profiles [@b0035], [@b0075].

Our understanding of the pathophysiology of CNS disorders and dementia has advanced dramatically during the last 30 years, especially in terms of their molecular pathogenesis and genetics. The drug treatment of CNS disorders has also made remarkable strides with the introduction of many new drugs for the treatment of schizophrenia, depression, anxiety, epilepsy, Parkinson's disease, and AD, among many other quantitatively and qualitatively important neuropsychiatric disorders.

Improvement in terms of clinical outcome, however, has fallen short of expectations, with up to one-third of patients continuing to experience clinical relapse or unacceptable medication-related side effects in spite of efforts to identify optimal treatment regimes with one or more drugs. Potential reasons for this historical setback might be: (1) that the molecular pathology of most CNS disorders is still poorly understood; (2) that drug targets are inappropriate, not fitting into the real etiology of the disease; (3) that most treatments are symptomatic but not antipathogenic; (4) that the genetic component of most CNS disorders is poorly defined; and (5) that the understanding of genome--drug interactions is very limited [@b0035], [@b0060].

The optimization of CNS therapeutics requires the establishment of new postulates regarding (1) the costs of medicines, (2) the assessment of protocols for multifactorial treatment in chronic disorders, (3) the implementation of novel therapeutics addressing causative factors, and (4) the establishment of pharmacogenomic strategies for drug development [@b0060]. Personalized therapeutics based on individual genomic profiles implies the characterization of five types of gene clusters:•Genes associated with disease pathogenesis•Genes associated with the mechanism of action of drugs•Genes associated with drug metabolism (phase I and II reactions)•Genes associated with drug transporters•Pleiotropic genes involved in multifaceted cascades and metabolic reactions

27.3. Genomics of Alzheimer's Disease {#s0015}
=====================================

More than 3000 genes distributed across the human genome have been screened for association with AD during the past 30 years [@b0080]. In the Alzgene database [@b0085] there are 695 genes potentially associated with AD, of which the top ten are (in decreasing order of importance): *APOE* (19q13.2), *BIN1* (2q14), *CLU* (8p21--p12), *ABCA7* (19p13.3), *CR1* (1q32), *PICALM* (11q14), *MS4A6A* (11q12.1), *CD33* (19q13.3), *MS4A4E* (11q12.2), and *CD2AP* (6p12). Potentially defective genes associated with AD represent about 1.39% (35,252.69 Kb) of the human genome, which is integrated by 36,505 genes (3,095,677.41 Kb). The highest number of AD-related defective genes concentrate on chromosomes 10 (5.41%; 7337.83 Kb), 21 (4.76%; 2289.15 Kb), 7 (1.62%; 2584.26 Kb), 2 (1.56%; 3799.67 Kb), 19 (1.45%; 854.54 Kb), 9 (1.42%; 2010.62 Kb), 15 (1.23%; 1264.4 Kb), 17 (1.19%; 970.16 Kb), 12 (1.17%; 1559.9 Kb), and 6 (1.15%; 1968.22 Kb), with the highest proportion (related to the total number of genes mapped on a single chromosome) located on chromosome 10 and the lowest on chromosome Y [@b0090] ([Figure 27.1](#f0005){ref-type="fig"} ).Figure 27.1Distribution of AD-related genes in the human genome.

The genetic and epigenetic defects identified in AD can be classified into four major categories: Mendelian mutations; susceptibility SNP; mtDNA mutations; and epigenetic changes. Mendelian mutations affect genes directly linked to AD, including 32 mutations in the amyloid beta precursor protein (*APP*) gene (21q21)(AD1), 165 mutations in the presenilin 1 (*PSEN1*) gene (14q24.3)(AD3), and 12 mutations in the presenilin 2 (*PSEN2*) gene (1q31--q42) (AD4) [@b0080], [@b0085], [@b0090], [@b0095], [@b0100]. *PSEN1* and *PSEN2* are important determinants of γ-secretase activity responsible for proteolytic cleavage of APP and NOTCH receptor proteins. Mendelian mutations are very rare in AD (1:1000). Mutations in exons 16 and 17 of the *APP* gene appear with a frequency of 0.30% and 0.78%, respectively, in AD patients. Likewise, *PSEN1*, *PSEN2*, and microtubule-associated protein Tau (*MAPT*)(17q21.1) mutations are present in less than 2% of cases. Mutations in these genes confer specific phenotypic profiles to patients with dementia: amyloidogeneic pathology associated with *APP*, *PSEN1*, and *PSEN2* mutations and tauopathy associated with *MAPT* mutations represent the two major pathogenic hypotheses for AD [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105].

Multiple polymorphic risk variants can increase neuronal vulnerability to premature death (see Appendix A). Among these susceptibility genes, the apolipoprotein E (*APOE*) gene (19q13.2)(AD2) is the most prevalent as a risk factor for AD, especially in those subjects harboring the *APOE-4* allele ([Figure 27.2](#f0010){ref-type="fig"} ), whereas carriers of the *APOE-2* allele might be protected against dementia. *APOE*-related pathogenic mechanisms are also associated with brain aging and with the neuropathological hallmarks of AD [@b0080].Figure 27.2Distribution and frequency of *APOE* genotypes in AD and vascular dementia.*Source: Adapted from Cacabelos*[@b0090].

27.4. Pathogenic Events {#s0020}
=======================

The dual amyloidogenic-tauopathic theory of AD has dominated the pathogenic universe of AD-related neurodegeneration (and divided the research community) for the past 50 years, nourished by the presence of *APP*, *PSEN1*, *PSEN2*, and *MAPT* mutations in a very small number of cases with early-onset AD. Nevertheless, this theory does not explain AD pathogenesis in full, and consequently novel (or complementary) theories have been emerging recently and during the past decades. A summary of the pathogenic events in AD is given in the following sections.

27.4.1. Genomic Defects {#s0025}
-----------------------

As a complex polygenic/multifactorial disorder, in which hundreds of polymorphic variants of risk might be involved (Appendix A, [Figure 27.1](#f0005){ref-type="fig"}), AD fulfils the "golden rule" of complex disorders, according to which the larger the number of genetic defects distributed in the human genome, the earlier the onset of the disease and the poorer its therapeutic response to conventional treatments; conversely, the smaller the number of pathogenic SNPs, the later the onset of the disease and the better its therapeutic response to different pharmacological interventions [@b0060], [@b0080], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140]. Genetic variation associated with different diseases interferes with microRNA-mediated regulation by creating, destroying, or modifying microRNA (miRNA) binding sites. miRNA-target variability is a ubiquitous phenomenon in the adult human brain which may influence gene expression in physiological and pathological conditions. AD-related SNPs interfere with miRNA gene regulation and affect AD susceptibility. Significant interactions include target SNPs present in seven genes related to AD prognosis with the miRNAs miR-214, -23a and -23b, -486-3p, -30e\*, -143, -128, -27a and -27b, -324-5p, and -422a. The dysregulated miRNA network contributes to aberrant gene expression in AD [@b0145], [@b0150], [@b0155].

27.4.2. Epigenetic Phenomena {#s0030}
----------------------------

Epigenetic factors have emerged as important mediators of development and aging, gene--gene and gene--environmental interactions, and the pathophysiology of complex disorders. Major epigenetic mechanisms (DNA methylation, histone modifications and chromatin remodeling, and noncoding RNA regulation) may contribute to AD pathology [@b0150], [@b0155].

27.4.3. Cerebrovascular Dysfunction {#s0035}
-----------------------------------

Vascular and metabolic dysfunctions are key components in AD pathology throughout the course of disease. Although common denominators between vascular and metabolic dysfunction are oxidative stress and Aβ [@b0160], genetic factors and cardiovascular risk factors may also account for the cerebrovascular damage present in AD [@b0165]. Inherited polymorphisms of the vascular susceptibility gene Ninjurin2 (*NINJ2*) are associated with AD risk [@b0170]. Endothelial dysfunction has been implicated as a crucial event in the development of AD.

Breakdown of the blood--brain barrier (BBB) as a result of disruption of tight junctions and transporters leads to increased leukocyte transmigration and is an early event in the pathology of many CNS disorders. BBB breakdown leads to neuroinflammation and oxidative stress, with mitochondrial dysfunction. The high concentration of mitochondria in cerebrovascular endothelial cells might account for the sensitivity of the BBB to oxidant stressors [@b0175], [@b0180].

Chronic brain hypoperfusion may be sufficient to induce premature neuronal death and dementia in vulnerable subjects [@b0080], [@b0115], [@b0120], [@b0125], [@b0185], [@b0190], [@b0195]. APOE-related changes in cortical oxygenation and hemoglobin consumption are evident, as revealed by brain optical topography analysis, and reflect that *APOE-4* carriers exhibit deficient brain hemodynamics and a poorer panneocortical oxygenation than do *APOE-3* or *APOE-2* carriers [@b0090]. Hypoperfusion in frontal, parietal, and temporal regions is a common finding in AD. White matter hyperintensities (WMH) correlate with age and with disease severity [@b0200].

Cerebral amyloid angiopathy (CAA) accounts for the majority of primary lobal intracerebral hemorrhages (ICH) among the elderly, and represents the cause of 20% of spontaneous ICHs in patients over 70 years of age. The basis for this disease process is the deposition and formation of eventually destructive amyloid plaques in the walls of brain vessels, predominantly arterial but not excluding venules and capillaries. CAA and CAA-associated microhemorrhages may also participate in the pathogenesis of AD [@b0205]. Aβ deposition in asymptomatic elderly individuals is associated with lobar MH (LMH).

LMH is present in 30.8% of AD, 35.7% of MCI, and 19.1% of controls [@b0210]. Neurovascular dysfunction in AD leads to reduced clearance across the BBB and accumulation of neurotoxic Aβ peptides in the brain. The ABC transport protein P-glycoprotein (P-gp, ABCB1) is involved in the export of Aβ from the brain into the blood. *P-gp*, *LRP1*, and *RAGE* mRNA expression is reduced in mice treated with Aβ~1--42~. In addition to the age-related decrease in P-gp expression, Aβ~1--42~ itself downregulates the expression of P-gp and other Aβ transporters, which could exacerbate the intracerebral accumulation of Aβ and thereby accelerate neurodegeneration in AD and cerebral β-amyloid angiopathy [@b0215].

27.4.4. Phenotypic Expression of Amyloid Deposits and Neurofibrillary Tangles {#s0040}
-----------------------------------------------------------------------------

β-Amyloid deposits in senile and neuritic plaques and hyperphosphorylated tau proteins in neurofibrillary tangles (NFT) are extracellular and intracellular expressions, respectively, of the AD neuropathological phenotype, together with selective neuronal loss in hippocampal and neocortical regions. Aβ plaque in the brain is the primary (postmortem) diagnostic criterion of AD. The main component of senile plaques is Aβ, a 39--43 amino acid peptide, generated by the proteolytic cleavage of amyloid precursor protein (APP) by the action of beta- and gamma-secretases. Aβ is neurotoxic, and this neurotoxicity is related to its aggregation state [@b0080], [@b0085], [@b0090], [@b0095], [@b0100], [@b0105].

27.4.5. Neuronal Apoptosis {#s0045}
--------------------------

Neuronal loss is a pathognomonic finding in AD and the final common path of multiple pathogenic mechanisms leading to neurodegeneration in dementia. Atrophy of the medial temporal lobe, especially the hippocampus and the parahippocampal gyrus, is considered to be AD's most predictive structural brain biomarker. The medial and posterior parts of the parietal lobe seem to be preferentially affected, compared to the other parietal lobe parts [@b0090].

27.4.6. Neurotransmitter Deficits {#s0050}
---------------------------------

An imbalance of different neurotransmitters (glutamate, acetylcholine, noradrenaline, dopamine, serotonin, and some neuropeptides) has been proposed as the neurobiological basis of behavioral symptoms in AD. Altered reuptake of neurotransmitters by vesicular glutamate transporters (VGLUTs), excitatory amino acid transporters (EAATs), the vesicular acetylcholine transporter (VAChT), the serotonin reuptake transporter (SERT), or the dopamine reuptake transporter (DAT) are involved in the neurotransmission imbalance in AD. Protein and mRNA levels of VGLUTs, EAAT1-3, VAChT, and SERT are reduced in the disease [@b0220].

27.4.7. Oxidative Stress {#s0055}
------------------------

Oxidative damage is a classic pathogenic mechanism of neurodegeneration [@b0180], [@b0225]. It is greater in brain tissue from patients with AD than age-matched controls. Tayler et al. [@b0230] studied the timing of this damage in relation to other pathogenic AD processes. Antioxidant capacity is elevated in AD and directly related to disease severity as indicated by the Braak tangle stage and the amount of insoluble Aβ. Accumulation of Aβ has been shown in brain mitochondria of AD patients and in AD transgenic mouse models. The presence of Aβ in mitochondria leads to free radical generation and neuronal stress.

A novel mitochondrial Aβ-degrading enzyme, presequence protease (Pre), has been identified in the mitochondrial matrix. hPreP activity is decreased in AD human brains and in the mitochondrial matrix of AD transgenic mouse brains (TgmAβPP and TgmAβPP/ABAD). Mitochondrial fractions isolated from AD brains and TgmAβPP mice have higher levels of 4-hydroxynonenal, an oxidative product. Cytochrome c oxidase activity is significantly reduced in the AD mitochondria. Decreased PreP proteolytic activity, possibly due to enhanced ROS production, may contribute to Aβ accumulation in mitochondria, leading to mitochondrial toxicity and neuronal death in AD [@b0235].

27.4.8. Cholesterol and Lipid Metabolism Dysfunction {#s0060}
----------------------------------------------------

Cholesterol seems to be intimately linked with the generation of amyloid plaques, which are central to AD pathogenesis. APOE variants are determinants in cholesterol metabolism and diverse forms of dyslipoproteinemia [@b0060], [@b0240]. Cholesterol protects the Aβ-induced neuronal membrane disruption and inhibits beta-sheet formation of Aβ on the lipid bilayer [@b0245]. Jones et al. [@b0250] found a significant over-representation of association signals in pathways related to cholesterol metabolism and the immune response in both of the two largest genome-wide association studies for LOAD.

27.4.9. Neuroinflammation and Immunopathology {#s0065}
---------------------------------------------

Several genes associated with immune regulation and inflammation show polymorphic variants of risk in AD, and abnormal levels of diverse cytokins have been reported in the brain, CSF, and plasma of AD patients [@b0080], [@b0115]. The activation of inflammatory cascades has been consistently demonstrated in AD pathophysiology, in which reactive microglia are associated with Aβ deposits and clearance. Resident microglia fail to trigger an effective phagocytic response to clear Aβ deposits, although they mainly exist in an "activated" state. Oligomeric Aβ (oAβ) can induce more potent neurotoxicity when compared with fibrillar Aβ (fAβ). Aβ~(1--42)~ fibrils, not Aβ~(1--42)~ oligomers, increase microglial phagocytosis [@b0255]. Among several putative neuroinflammatory mechanisms, the TNF-α signaling system has a central role in this process. In AD, TNF-α levels are altered in serum and CSF. The abnormal production of inflammatory factors may accompany the progression from mild cognitive impairment (MCI) to dementia. Abnormal activation of the TNF-α signaling system, represented by increased expression of sTNFR1, is associated with a higher risk of progression from MCI to AD [@b0260].

27.4.10. Neurotoxic Factors {#s0070}
---------------------------

Old and new theories suggest that different toxic agents, from metals (e.g., aluminium, copper, zinc, iron) to biotoxins and pesticides, might contribute to neurodegeneration. Dysfunctional homeostasis of transition metals is believed to play a role in AD pathogenesis [@b0090].

27.4.11. Other Players {#s0075}
----------------------

Many novel pathogenic mechanisms potentially involved in AD neurodegeneration have been proposed in recent times. Moreover, there has been a revival of some old hypotheses. Examples of pathogenic players in AD, other than those just discussed, include the Ca^2+^ hypothesis, insulin resistance, NGF imbalance, glycogen synthase kinase-3 (GSK-3), advanced glycation end products (AGEs) and their receptors (RAGE), the efflux transporter P-glycoprotein (P-gp), c-Abl tyrosine kinase, post-transcriptional protein alterations that compromise the proteasome system and the chaperone machinery (HSPB8--BAG3), autophagy as a novel Aβ-generating pathway, hypocretin (orexin), cathepsin B, Nogo receptor proteins, adipocytokines and CD34^+^ progenitor cells, CD147, impairment of synaptic plasticity (PSD-95), anomalies in neuronal cell division and apoptosis, stem cell factor (SCF), telomere shortening, deficiency in repair of nuclear and mitochondrial DNA damage, and microDNAs [@b0090].

27.5. Biomarkers and Comorbidity {#s0080}
================================

AD's phenotypic features represent the biomarkers to be used as diagnostic predictors and the expression of pathogenic events to be modified with an effective therapeutic intervention. Important differences have been found in the AD population (as compared with healthy subjects) in different biological parameters, including blood pressure, glucose, cholesterol and triglyceride levels, transaminase activity, hematological parameters, metabolic factors, thyroid function, brain hemodynamic parameters, and brain mapping activity [@b0035], [@b0115], [@b0120], [@b0125], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295].

These clinical differences are clear signs of comorbidity rather than typical features of AD. Blood pressure values, glucose levels, and cholesterol levels are higher in AD than in healthy elderly subjects. Approximately 20% of AD patients are hypertensive, 25% are diabetics, 50% are hypercholesterolemic, and 23% are hypertriglyceridemic. More than 25% of patients exhibit high GGT activity, 5--10% show anemic conditions, 30--50% show an abnormal cerebrovascular function characterized by poor brain perfusion, and more than 60% have an abnormal electroencephalographic pattern, especially in frontal, temporal, and parietal regions, as revealed by quantitative EEG (qEEG) or computerized mapping [@b0035], [@b0060], [@b0115], [@b0270]. Significant differences are currently seen between females and males, indicating the effect of gender on the phenotypic expression of the disease. In fact, the prevalence of dementia is 10--15% higher in females than in males from 65--85 years of age. All of these parameters are highly relevant when treating AD patients, because some of them reflect a concomitant pathology that also needs therapeutic consideration.

AD biomarkers can be differentiated into several categories: (1) neuropathological markers; (2) structural and functional neuroimaging markers; (3) neurophysiological markers (EEG, qEEG, brain mapping); (4) biochemical markers in body fluids (e.g., blood, urine, saliva, CSF); and (5) genomic markers (structural and functional genomics, proteomics, metabolomics).

27.5.1. Neuropathology {#s0085}
----------------------

Plaques and tangles in the hippocampus and cortex are still considered the seminal findings in AD neuropathology and are the conventional means of establishing the boundary between amyloidopathies and tauopathies; however, both phenotypic markers are also present in normal brains, in more than 60% of cases with traumatic brain injury, and in many other brain disorders [@b0300].

27.5.2. Structural and Functional Neuroimaging {#s0090}
----------------------------------------------

Structural and functional neuroimaging techniques (MRI, fMRI, PET, SPECT) are essential tools in the diagnosis of dementia, although the specificity of visual observations in degenerative forms of dementia is of doubtful value. Nevertheless, these procedures are irreplaceable for a differential diagnosis. There is a characteristic regional impairment in AD that involves mainly the temporo--parietal association cortices, the mesial temporal structures, and, to a more variable degree, the frontal association cortex. This pattern of functional impairment can provide a biomarker for diagnosis of AD and other neurodegenerative dementias at the clinical stage of mild cognitive impairment, and for monitoring its progression. Healthy young *APOE ɛ4* carriers have smaller hippocampal volumes than *APOE ɛ2* carriers.

The difference in hippocampal morphology is cognitively/clinically silent in young adulthood, but can render *APOE ɛ4* carriers more prone to the later development of AD, possibly because of lower reserve cognitive capacity [@b0305]. LOAD patients exhibit a selective parahippocampal white matter (WM) loss, while EOAD patients experience a more widespread pattern of posterior WM atrophy. The distinct regional distribution of WM atrophy reflects the topography of gray matter (GM) loss. *ApoE ɛ4* status is associated with a greater parahippocampal WM loss in AD. The greater WM atrophy in EOAD than in LOAD fits with the evidence that EOAD is a more aggressive form of the disease [@b0310]. FDG-PET is quantitatively more accurate than perfusion SPECT.

Regional metabolic and blood flow changes are closely related to clinical symptoms, and most areas involved in these changes also develop significant cortical atrophy. FDG-PET is complementary to amyloid PET, which targets a molecular marker that does not have a close relation to current symptoms. FDG-PET is expected to play an increasing role in diagnosing patients at an early stage of AD and in clinical trials of drugs aimed at preventing or delaying the onset of dementia [@b0315]. Functional neuroimaging biomarkers are becoming popular, with the introduction of novel tracers for brain amyloid deposits. Amyloid deposition causes severe damage to neurons many years before onset of dementia via a cascade of several downstream effects.

Positron emission tomography (PET) tracers for amyloid plaque are desirable for early diagnosis of AD, particularly to enable preventative treatment once effective therapeutics is available. The amyloid imaging tracers flutemetamol, florbetapir, and florbetaben labeled with ^18^F have been developed for PET. These tracers are currently undergoing formal clinical trials to establish whether they can be used to accurately image fibrillary amyloid, and to distinguish patients with AD from normal controls and those with other diseases that cause dementia [@b0315].

27.5.3. Neurophysiology {#s0095}
-----------------------

There is a renewed interest in the use of computerized brain mapping as a diagnostic aid and as a monitoring tool in AD [@b0320]. Electroencephalography (EEG) studies in AD show an attenuation of average power within the alpha band (7.5--13 Hz) and an increase in power in the theta band (4--7 Hz) [@b0325]. *APOE* genotypes influence brain bioelectrical activity in AD. In general, *APOE-4* carriers tend to exhibit a slower EEG pattern from early stages [@b0080], [@b0090], [@b0330].

27.5.4. Biochemistry of Body Fluids {#s0100}
-----------------------------------

Other biomarkers of potential interest include cerebrospinal fluid (CSF) and peripheral levels of Aβ~42~, protein tau, histamine, interleukins, and some other novel candidate markers such as chitinase 3-like 1 (CHI3L1) protein [@b0035], [@b0080], [@b0125], [@b0335], [@b0340], [@b0345]. The concentration of the 42-amino-acid form of Aβ (Aβ~1--42~) is reduced in the CSF of AD patients, which is believed to reflect the AD pathology, with plaques in the brain acting as sinks. Novel C-truncated forms of Aβ (Aβ~1--14~, Aβ~1--15~, and Aβ~1--16~) were identified in human CSF. The presence of these small peptides is consistent with a catabolic amyloid precursor protein cleavage pathway by β- followed by α-secretase. Aβ~1--14~, Aβ~1--15~, and Aβ~1--16~ increase dose-dependently in response to γ-secretase inhibitor treatment, while Aβ~1--42~ levels are unchanged [@b0350].

Kester et al. [@b0355] investigated change over time in CSF levels of amyloid-beta 40 and 42 (Aβ~40~ and Aβ~42~), total tau (tau), tau phosphorylated at threonine 181 (ptau-181), isoprostane, neurofilaments heavy (NfH) and neurofilaments light (NfL). Aβ~42~, tau, and tau phosphorylated at threonine 181 differentiated between diagnosis groups, whereas isoprostane, NfH, and NfL did not. In contrast, effects of follow-up time were found only for nonspecific CSF biomarkers: levels of NfL decreased, and levels of isoprostane, Aβ~40~, and tau increased over time. An increase in isoprostane was associated with progression of mild cognitive impairment in AD and with cognitive decline. Contrary to AD-specific markers, nonspecific CSF biomarkers show change over time, which potentially can be used to monitor disease progression in AD.

27.5.5. Genomics and Proteomics {#s0105}
-------------------------------

Structural markers are represented by SNPs in genes associated with AD, polygenic cluster analysis, and genome-wide studies (GWSs). Functional markers attempt to correlate genetic defects with specific phenotypes (genotype--phenotype correlations). In proteomic studies, several candidate CSF protein biomarkers have been assessed in neuropathologically confirmed AD, nondemented (ND) elderly controls, and non-AD dementias (NADD). Markers selected included apolipoprotein A-1 (ApoA1), hemopexin (HPX), transthyretin (TTR), pigment epithelium-derived factor (PEDF), Aβ~1--40~, Aβ~1--42~, total tau, phosphorylated tau, α-1 acid glycoprotein (A1GP), haptoglobin, zinc α-2 glycoprotein (Z2GP), and apolipoprotein E (ApoE). Concentrations of Aβ~1--42~, ApoA1, A1GP, ApoE, HPX, and Z2GP differed significantly among AD, ND, and NADD subjects. The CSF concentrations of these three markers distinguished AD from ND subjects with 84% sensitivity and 72% specificity, with 78% of subjects correctly classified.

By comparison, Aβ~1--42~ alone gave 79% sensitivity and 61% specificity, with 68% of subjects correctly classified. For the diagnostic discrimination of AD from NADD, only the concentration of Aβ~1--42~ was significantly related to diagnosis, with a sensitivity of 58% and a specificity of 86% [@b0360]. Carrying the *APOE-ɛ4* allele was associated with a significant decrease in CSF Aβ~1--42~ concentrations in middle-aged and older subjects. In AD, Aβ~1--42~ levels are significantly lower in *APOEɛ4* carriers compared to noncarriers. These findings demonstrate significant age effects on CSF Aβ~1--42~ and pTau181 across the lifespan, and also suggest that a decrease in Aβ~1--42~, but an increase in pTau181 CSF levels, is accelerated by the *APOEɛ4* genotype in middle-aged and older adults with normal cognition [@b0365].

Han et al. [@b0370] carried out a GWAS to better define the genetic backgrounds of normal cognition, mild cognitive impairment (MCI), and AD in terms of changes in CSF levels of Aβ~1--42~, T-tau, and P-tau181P. CSF Aβ~1--42~ levels decreased with *APOE* gene dose for each subject group. T-tau levels tended to be higher among AD cases than among normal subjects. *CYP19A1* "aromatase" (rs2899472), *NCAM2*, and multiple SNPs located on chromosome 10 near the *ARL5B* gene demonstrated the strongest associations with Aβ~1--42~ in normal subjects.

Two genes found to be near the top SNPs, *CYP19A1* (rs2899472) and *NCAM2* (rs1022442), have been reported as genetic factors related to the progression of AD. In AD subjects, *APOE ɛ2/ɛ3* and *ɛ2/ɛ4* genotypes were associated with elevated T-tau levels, and the *ɛ4/ɛ4* genotype was associated with elevated T-tau and P-tau181P levels. Blood-based markers reflecting core pathological features of AD in presymptomatic individuals are likely to accelerate the development of disease-modifying treatments.

Thambisetty et al. [@b0375] performed a proteomic analysis to discover plasma proteins associated with brain Aβ burden in nondemented older individuals. A panel of 18 2DGE plasma protein spots effectively discriminated between individuals with high and low brain Aβ. Mass spectrometry identified these proteins, many of which have established roles in Aβ clearance, including a strong signal from ApoE. A strong association was observed between plasma ApoE concentration, and Aβ burden in the medial temporal lobe. Targeted voxel-based analysis localized this association to the hippocampus and entorhinal cortex. *APOE ɛ4* carriers also showed greater Aβ levels in several brain regions relative to *ɛ4* noncarriers. Both peripheral concentration of the ApoE protein and the *APOE* genotype may be related to early neuropathological changes in brain regions vulnerable to AD pathology even in the nondemented elderly.

27.6. Therapeutic Strategies {#s0110}
============================

Modern therapeutic strategies in AD are aimed at interfering with the main pathogenic mechanisms potentially involved in AD [@b0035], [@b0060], [@b0080], [@b0090], [@b0115], [@b0120], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295] ([Box 27.1](#x0005){ref-type="boxed-text"}). Starting in the early 1990s, the neuropharmacology of AD was dominated by acetylcholinesterase inhibitors, represented by tacrine, donepezil, rivastigmine, and galantamine [@b0380], [@b0385], [@b0390]. Memantine, a partial NMDA antagonist, was introduced in the 2000s for the treatment of severe dementia [@b0395]; and the first clinical trials with immunotherapy, to reduce amyloid burden in senile plaques, were withdrawn due to severe ADRs [@b0400], [@b0405]. After the initial promise of β- and γ-secretase inhibitors [@b0410], [@b0415] and novel vaccines [@b0420], [@b0425] devoid of severe side effects, during the past few years no relevant drug candidates have dazzled the scientific community with their capacity to halt disease progression; however, a large number of novel therapeutic strategies for the pharmacological treatment of AD have been postulated, with some apparent effects in preclinical studies (see [Box 27.1](#x0005){ref-type="boxed-text"}).Box 27.1Experimental Strategies for the Pharmacological Treatment of Alzheimer's DiseaseNew cholinesterase inhibitorsCholinergic receptor agonistsMonoamine regulatorsDiverse natural compounds derived from vegetal sources:Alkaloids from the calabar bean (*Physostigma venenosum*)Huperzine A from *Huperzia serrata*Galantamine from the snowdrop *Galanthus woronowii*Cannabinoids (cannabidiol) from *Cannabis sativa*Saffron (*Crocus sativus*)Ginseng (*Panax species*)Sage (*Salvia species*)Lemon balm (*Melissa officinalis*)*Polygala tenuifolia*Nicotine from *Nicotiana species*Grape seed polyphenolic extractsFuzhisan, a Chinese herbal medicineResveratrolXanthocerasideGarlic (*Allium sativum*)Linarin from *Mentha arvensis* and *Buddleja davidii*Carotenoids (e.g., retinoic acid, all-trans retinoic acid, lycopene and β-carotene)Curcumin from the rhizome of *Curcuma longa*Decursinol from the roots of *Angelica gigas*Bacopa monniera LINN *(Syn. Brahmi)*Olive oilPhytoestrogensWalnut extract*Erigeron annuus* leaf extractsEpigallocatechin-3-gallateLuteolinThe brown algae (*Ecklonia cava*)Gami-Chunghyuldan (standardized multiherbal medicinal formula)*Punica granatum* extractsPlants of different origin:Yizhi JiannaoDrumstick tree (*Moringa oleifera*)Ginkgo/Maidenhair tree (*Ginkgo biloba*)Sicklepod (*Cassia obtisufolia*)Sal Leaved Desmodium (*Desmodium gangeticum*)Lemon Balm (*Melissa officinalis*)Garden sage, common sage (*Salvia officinalis*)Immunotherapy and treatment options for tauopathies:Tau kinase inhibitors2-AminothiazolesPhosphoprotein phosphatase 2A (PP2A) inhibitorsc-Jun N-terminal kinase (JNKs) inhibitorsp38 MAP kinase inhibitors (CNI-1493)Harmine (β-carboline alkaloid)Immunotherapy and Aβ breakers for AD-related amyloidopathy:Active and passive immunizationSecretase inhibitors (β- and γ-)NeostatinsNeurosteroidsPhosphodiesterase inhibitorsProtein phosphatase methylesterase-1 inhibitorsHistone deacetylase inhibitorsmTOR inhibitorsPeroxisome proliferator-activated receptor agonistsP-glycoprotein regulatorsNuclear receptor agonistsGlycogen synthase kinase-3β (GSK-3β) regulatorsHistamine H3 receptor inverse agonistsEstrogensKynurenine 3-monooxygenase inhibitorsChaperones (small heat shock proteins (sHSPs); Hsp90 inhibitors and HSP inducers)microRNAs (miRNAs) and gene silencing (RNA interference)(RNAi)Miscellaneous strategies:Sodium fullerenolateGlucagon-like peptide -1 (GLP-1)ChemokinesMacrophage inflammatory protein-2 (MIP-2)Stromal cell-derived factor-1α (SDF-1α)Cyclooxygenase-1 and cyclooxygenase-2 inhibitorsBone morphogenetic protein 9 (BMP-9)Granulocyte colony stimulating factor (G-CSF)/AMD3100 (CXCR4 antagonist)Vitamins (A, B, C, D)ω-3 Polyunsaturated fatty acids (n-3 PUFAs)Docosahexaenoic acid (DHA, C22:6 n-3)SphingosylphosphorylcholineCitidine-5-diphosphocholine (CDP-choline)Cathepsin B inhibitorsPituitary adenylate cyclase--activating polypeptideNAP (Davunetide)Transcription factor specificity protein 1 (Sp1) inhibitors (tolfenamic acid)TNF inhibitors:2-(2,6-Dioxopiperidin-3-yl)phthalimidine EM-12 dithiocarbamatesN-substituted 3-(Phthalimidinp-2-yl)-2,6-dioxopiperidines3-substituted 2,6-DioxopiperidinesPyrrolo\[3,2-e\]\[1,2,4\]triazolo\[1,5-a\]pyrimidine (SEN1176)LatrepirdineLeucettinesDihydropyridines (inhibitors of L-type calcium channels)Brain-penetrating angiotensin-converting enzyme (ACE) inhibitorsNADPH oxidase inhibitors (Apocynin)Heterocyclic indazole derivatives (inhibitors of serum- and glucocorticoid-inducible-kinase 1 \[*SGK1*\])IgG-single-chain Fv fusion proteins

27.6.1. Immunotherapy {#s0115}
---------------------

There are two main modalities of immunotherapy for AD: (1) passive immunotherapy, with the administration of monoclonal Aβ-specific antibodies [@b0430]; and (2) active immunization with the Aβ~42~ antigen [@b0435], [@b0440] or Aβ-conjugated synthetic fragments bound to a carrier protein, thus avoiding potential problems associated with mounting a T-cell response directly against Aβ [@b0445]. A new approach---delivering Aβ~42~ in a novel immunogen-adjuvant manner consisting of sphingosine-1-phosphate (S1P)-containing liposomes, administered to APP/PS1 transgenic mice before and after the detection of AD-like pathology in the brain---has recently been developed [@b0425].

The results from this novel vaccine (EB101) indicate that active immunization significantly prevents and reverses the progression of AD-like pathology and also clears prototypical neuropathological hallmarks in transgenic mice. This new approach strongly induces T-cell, B-cell, and microglial immune response activation, avoiding the Th1 inflammatory reaction [@b0450].

The rationale for amyloid immunotherapy in AD [@b0455] is based on the following assumptions:•β-amyloid plaques and their aggregated, proto-fibrillar, and oligomeric precursors contain immunologic neo-epitopes that are absent from the full-length amyloid precursor protein (APP), as well as from its soluble proteolytic derivatives restricted to brain tissue; consequently, β-amyloid-based immunotherapies designed to selectively target pathologic neo-epitopes present on Aβ oligomers, protofibrils, or fibrils should not cause autoimmune disease in unaffected tissues throughout the organism•β-amyloid buildup precedes neurodegeneration and functional loss, and either the prevention of its formation or its removal can be expected to result in the slowing or the prevention of neurodegeneration•β-amyloid can cause the formation of neurofibrillary tangles in vivo and in vitro. The removal of β-amyloid, or the prevention of its buildup, has the potential not only to correct β-amyloid-related toxicity, but also to prevent the formation of neurofibrillary tangles•Conformational changes of endogenously occurring proteins and the formation of insoluble aggregates are commonly associated with neurodegeneration and brain disease, so the removal or prevention of these pathologic protein aggregates is also a therapeutic goal in the principle of immunotherapy•Immunotherapy works in experimental animals and in initial clinical trials: both active immunization and passive antibody transfer consistently reduce brain β-amyloid load, improve β-amyloid-related memory impairments, and protect neurons against degeneration in many independent experiments using different mouse models and primates [@b0450]

Since Aβ immunotherapy has a limited clearance effect of tau aggregates in dystrophic neurites, the development of an alternative therapy that directly targets pathological tau has become crucial. Increased levels of tau oligomers have been observed in the early stage of AD, prior to the detection of neurofibrillary tangles (NFT) formed by aggregation and accumulation of the microtubule-associated protein tau [@b0460]. Several approaches have been taken to treat AD by targeting tau, such as the following:1.The inhibition of tau hyperphosphorylation, by a kinase inhibitor of soluble aggregated tau formation, which also prevents related motor deficits [@b0465].2.Activation of the proteolytic pathway, by the degrading action of calpain [@b0470] and puromycin-sensitive aminopeptidase [@b0475].3.The stabilization of microtubules, treating tauopathies by functionally binding and stabilizing microtubules with mt-binding protein tau [@b0480] and paclitaxel, a drug proven effective in restoring affected axonal transport and motor impairments [@b0485].4.Tau clearance by immunotherapy in this case, the tau active vaccination uses phosphorylated antigens of tau fragments associated with neurofibrillary tangles [@b0490] that results in an efficient reduction of both soluble and insoluble tau active fragments, reducing phosphorylated NFTs in AD-like mouse brains.

Preclinical studies have shown clear evidence that Aβ immunization therapy provides protection and reverses the pathological effects of AD in transgenic mouse models [@b0495]. This strategy seems to improve cognition performance [@b0500] after Aβ~42~ immunization, in addition to causing an effective reduction in Aβ pathology. A recent immunization study has proven that a fragment of the Aβ peptide bound to polylysines activates the immune response that diminishes AD-like pathology in APP transgenic mice. This result reinforces the notion that the immune-conjugate approach is an effective means of Aβ immunotherapy, and also that the entire Aβ peptide is not necessary for its efficacy. It is in accordance with the hypothesis that specific antibodies directed against the amino-terminal and/or central region of the amyloid peptide provide beneficial protection against amyloid pathology. Passive immunization studies have also been conducted with promising experimental results, showing that a humoral response alone, without Aβ cellular response, is sufficient to reduce the β-amyloid burden and reverse memory deficits [@b0505].

Among the drugs and vaccines currently under development to treat the pathological effects of AD, the most promising are bapineuzumab, solanezumab, CAD106, and EB101. Solanezumab is a monoclonal antibody raised against Aβ~13--28~ that recognizes an epitope in the core of the amyloid peptide, binding selectively to soluble Aβ and with low affinity for the fibrillar Aβ form [@b0510]. Thus, it presents fewer adverse events than does bapineuzumab, which binds to Aβ amyloid plaques more strongly than soluble Aβ [@b0515]. There are a few other monoclonal antibodies against Aβ that have properties different from those of bapineuzumab, such as PF-04360365, which specifically targets the free carboxy-terminus of Aβ~1--40~, MABT5102A, which binds with equally high affinity to Aβ monomers, oligomers, and fibrils, and GSK933776A, which targets the N-terminus of Aβ.

Specific anti-Aβ antibodies are present in pooled preparations of intravenous immunoglobulin (IVIg or IGIV), which has already been approved by the FDA for the treatment of a variety of neurological conditions. Current results from these studies have shown that IVIg treatment may also be an efficacious alternative approach in the treatment of AD neuropathologies [@b0450], [@b0520].

Avoiding both the strong Th1 effects of the QS-21 adjuvant and the T-cell epitopes at the C-terminus of Aβ, CAD106 consists of a short N-terminal fragment of Aβ attached to a virus-like particle, with no additional adjuvant [@b0525]. This therapeutic agent is currently in phase II trials. Affiris is testing two short 6-amino-peptides (AD01, AD02), administered with aluminum hydroxide as adjuvant, that mimic the free N-terminus of Aβ and therefore cause cross-reactivity with the native peptide in phase I trials [@b0530]. In terms of prevention and therapeutic treatment, the EB101 vaccine showed for the first time the effectiveness of combining a liposomal immunogen-adjuvant with an Aβ antigen to induce an effective immunological response combined with an anti-inflammatory effect in preclinical studies using APP/PS1 transgenic mice [@b0425], [@b0450].

The EB101 vaccine immunization process has shown a marked positive effect as a preventive and therapeutic treatment, reducing amyloidosis-induced inflammation as an effective Th2 immunomodulator. Moreover, this vaccine proved to stimulate innate immunity and enable effective phagocytosis to clear amyloid and neurofibrillary tangles, which are among the major hallmarks of AD-like neuropathology observed. A few other vaccines are currently under development, and recent studies have opened up new perspectives in the immunization approach to AD pathology; in particular, gene-gun-mediated genetic immunization with the Aβ~42~ gene [@b0535] shows that self-tolerance can be broken in order to produce a humoral response to the Aβ~42~ peptide with minimal cellular response.

27.7. Pharmacogenomics {#s0120}
======================

AD patients may take 6--12 different drugs per day for the treatment of dementia-related symptoms, including memory decline (conventional antidementia drugs, neuroprotectants), behavioral changes (antidepressants, neuroleptics, sedatives, hypnotics), and functional decline. Such drugs may also be taken for the treatment of concomitant pathologies (epilepsy, cardiovascular and cerebrovascular disorders, parkinsonism, hypertension, dyslipidemia, anemia, arthrosis, etc). The co-administration of several drugs may cause side effects and ADRs in more than 60% of AD patients, who in 2--10% of cases require hospitalization. In more than 20% of patients, behavioral deterioration and psychomotor function can be severely altered by polypharmacy. The principal causes of these iatrogenic effects are (1) the inappropriate combination of drugs, and (2) the genomic background of the patient, which is responsible for his/her pharmacogenomic outcome.

Pharmacogenomics account for 30--90% of the variability in pharmacokinetics and pharmacodynamics. The genes involved in the pharmacogenomic response to drugs in AD fall into five major categories:•Genes associated with AD pathogenesis and neurodegeneration (*APP*, *PSEN1*, *PSEN2*, *MAPT*, *PRNP*, *APOE*, and others)•Genes associated with the mechanism of action of drugs (enzymes, receptors, transmitters, messengers)•Genes associated with drug metabolism (phase I (*CYP*s) and phase II reactions (*UGT*s, *NAT*s))•Genes associated with drug transporters (*ABC*s, *SLC*s)•Pleiotropic genes involved in multifaceted cascades and metabolic reactions (*APOs*, *ILs*, *MTHFR*, *ACE*, *AGT*, *NOS*, etc) [@b0090] ([Figure 27.1](#f0005){ref-type="fig"})

27.7.1. Pathogenic Genes {#s0125}
------------------------

In more than 100 clinical trials for dementia, *APOE* has been used as the only gene of reference for the pharmacogenomics of AD [@b0035], [@b0060], [@b0075], [@b0080], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295]. Several studies indicate that the presence of the *APOE-4* allele differentially affects the quality and extent of drug responsiveness in AD patients treated with cholinergic enhancers (tacrine, donepezil, galantamine, rivastigmine), neuroprotective compounds (nootropics), endogenous nucleotides (CDP-choline), immunotrophins (anapsos), neurotrophic factors (cerebrolysin), rosiglitazone, or combination therapies [@b0540], [@b0545], [@b0550]; however, controversial results are frequently found that are due to methodological problems, study design, and patient recruitment in clinical trials.

The major conclusion in most studies is that *APOE-4* carriers are the worst responders to conventional treatments [@b0035], [@b0060], [@b0075], [@b0080], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295]. When *APOE* and *CYP2D6* genotypes are integrated in bigenic clusters and the *APOE*+*CYP2D6*-related therapeutic response to a combination therapy is analyzed in AD patients, it becomes clear that the presence of the *APOE-4/4* genotype is able to convert pure *CYP2D6\*1/\*1* extensive metabolizers (EMs) into full poor responders to conventional treatments, indicating the existence of a powerful influence of the *APOE-4* homozygous genotype on the drug-metabolizing capacity of pure *CYP2D6* EMs. In addition, a clear accumulation of *APOE-4/4* genotypes is observed among *CYP2D6* poor (PMs) and ultrarapid metabolizers (UMs) [@b0060].

27.7.2. Genes Involved in the Mechanism of Action of CNS Drugs {#s0130}
--------------------------------------------------------------

Most genes associated with the mechanism of action of CNS drugs encode receptors, enzymes, and neurotransmitters on which psychotropic drugs act as ligands (agonists, antagonists), enzyme modulators (substrates, inhibitors, inducers), or neurotransmitter regulators (releasers, reuptake inhibitors) [@b0555]. In the case of conventional antidementia drugs, tacrine, donepezil, rivastigmine and galantamine are cholinesterase inhibitors, and memantine is a partial NMDA antagonist ([Table 27.1](#t0010){ref-type="table"} ).Table 27.1Pharmacogenomic Profile of Antidementia DrugsDonepezil**CategoryAntidementia agent/cholinesterase inhibitor**MechanismCentrally active, reversible acetylcholinesterase inhibitor; increases acetylcholine available for synaptic transmission in CNS**Genes**PathogenicAPOE, CHATMechanisticCHAT, ACHE, BCHEMetabolism: substrateCYP2D6 (major), CYP3A4 (major), UGTs, ACHEMetabolism: inhibitorACHE, BCHETransporterABCB1**GalantamineCategoryAntidementia agent/cholinesterase inhibitor**MechanismReversible and competitive acetylcholinesterase inhibition leading to increased concentration of acetylcholine at cholinergic synapses; modulates nicotinic acetylcholine receptor; may increase glutamate and serotonin levels**Genes**MechanisticAPOE, APPPathogenicACHE, BCHE, CHRNA4, CHRNA7, CHRNB2Metabolism: substrateCYP2D6 (major), CYP3A4 (major), UGT1A1Metabolism: inhibitorACHE, BCHE**MemantineCategoryAntidementia Drug; N-methyl-d-aspartate Receptor Antagonist**MechanismBinds preferentially to NMDA receptor-operated cation channels; may act by blocking glutamate actions, mediated in part by NMDA receptors. Antagonists: GRIN2A, GRIN2B, GRIN3A, HTR3A, CHRFAM7A**Genes**PathogenicAPOE, PSEN1, MAPTMechanisticGRIN2A, GRIN2B, GRIN3A, HTR3A, CHRFAM7AMetabolism: inhibitorCYP1A2 (weak), CYP2A6 (weak), CYP2B6 (strong), CYP2C9 (weak), CYP2C19 (weak), CYP2D6 (strong), CYP2E1 (weak), CYP3A4 (weak)PleiotropicAPOE, MAPT, MT-TK, PSEN1**RivastigmineCategoryAntidementia Agent/Cholinesterase Inhibitor**MechanismIncreases acetylcholine in CNS through reversible inhibition of its hydrolysis by cholinesterase**Genes**PathogenicAPOE, APP, CHATMechanisticACHE, BCHE, CHAT, CHRNA4, CHRNB2Metabolism: inhibitorACHE, BCHEPleiotropicAPOE, MAPT**TacrineCategoryAntidementia agent/cholinesterase inhibitor**MechanismElevates acetylcholine in cerebral cortex by slowing degradation of acetylcholine**Genes**PathogenicAPOEMechanisticACHE, BCHE, CHRNA4, CHRNB2Metabolism: substrateCYP1A2 (major), CYP2D6 (minor), CYP3A4 (major)Metabolism: inhibitorACHE, BCHE, CYP1A2 (weak)TransporterSCN1APleiotropicAPOE, MTHFR, CES1, LEPR, GSTM1, GSTT1**Source:** Cacabelos [@b0565].

27.7.3. Genes Involved in Drug Metabolism {#s0135}
-----------------------------------------

Drug metabolism includes phase I reactions (i.e., oxidation, reduction, hydrolysis) and phase II conjugation reactions (i.e., acetylation, glucuronidation, sulphation, methylation) ([Table 27.2](#t0015){ref-type="table"} ). The principal enzymes with polymorphic variants involved in phase I reactions are the following: cytochrome P450 monooxygenases (CYP3A4/5/7, CYP2E1, CYP2D6, CYP2C19, CYP2C9, CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1/2), epoxide hydrolase, esterases, NQO1 (NADPH-quinone oxidoreductase), DPD (dihydropyrimidine dehydrogenase), ADH (alcohol dehydrogenase), and ALDH (aldehyde dehydrogenase). The major enzymes involved in phase II reactions include UGTs (uridine 5′-triphosphate glucuronosyl transferases), TPMT (thiopurine methyltransferase), COMT (catechol-O-methyltransferase), HMT (histamine methyl-transferase), STs (sulfotransferases), GST-A (glutathione S-transferase A), GST-P, GST-T, GST-M, NAT1 (N-acetyl transferase 1), NAT2, and others ([Table 27.2](#t0015){ref-type="table"}).Table 27.2Drug Metabolism-Related GenesPhase I EnzymesAlcohol dehydrogenasesADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, ADH7, ADHFE1Aldehyde dehydrogenasesALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, ALDH3A1, ALDH3A2, ALDH3B1, ALDH3B2, ALDH4A1, ALDH5A1, ALDH6A1, ALDH7A1, ALDH8A1, ALDH9A1, AOX1Aldo-keto reductasesAKR1A1, AKR1B1, AKR1C1, AKR1D1Amine oxidasesMAOA, MAOB, SMOXCarbonyl reductasesCBR1, CBR3, CBR4Cytidine deaminaseCDACytochrome P450 familyCYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A7, CYP2A13, CYP2B6, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2D7P1, CYP2E1, CYP2F1, CYP2J2, CYP2R1, CYP2S1, CYP2W1, CYP3A4, CYP3A5, CYP3A7, CYP3A43, CYP4A11, CYP4A22, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4Z1, CYP7A1, CYP7B1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17A1, CYP19A1, CYP20A1, CYP21A2, CYP24A1, CYP26A1, CYP26B1, CYP26C1, CYP27A1, CYP27B1, CYP39A1, CYP46A1, CYP51A1, POR, TBXAS1Cytochrome b5 reductaseCYB5R3Dihydropyrimidine dehydrogenaseDPYDEsterasesAADAC, CEL, CES1, CES1P1, CES2, CES3, CES5A, ESD, GZMA, GZMB, PON1, PON2, PON3, UCHL1, UCHL3EpoxidasesEPHX1, EPHX2Flavin-containing monooxygenasesFMO1, FMO2, FMO3, FMO4, FMO5, FMO6PGlutathione reductase/peroxidasesGSR, GPX1, GPX2, GPX3, GPX4, GPX5, GPX6, GPX7PeptidasesDPEP1, METAP1Prostaglandin-endoperoxide synthasesPTGS1, PTGS2Short-chain dehydrogenases/reductasesDHRS1, DHRS2, DHRS3, DHRS4, DHRS7, DHRS9, DHRS12, DHRS13, DHRSX, HSD11B1, HSD17B10, HSD17B11, HSD17B14Superoxide dismutaseSOD1, SOD2Xanthine dehydrogenaseXDH**Phase II Enzymes**Amino acid transferasesAGXT, BAAT, CCBL1DehydrogenasesNQO1, NQO2, XDHEsterasesCES1, CES2, CES3, CES4, CES5AGlucuronosyl transferasesDDOST, UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT2A1, UGT2A3, UGT2B10, UGT2B11, UGT2B15, UGT2B17, UGT2B28, UGT2B4, UGT2B7, UGT3A1, UGT8Glutathione transferasesGSTA1, GSTA2, GSTA3, GSTA4, GSTA5, GSTCD, GSTK1, GSTM1, GSTM2, GSTM3, GSTM4, GSTM5, GSTO1, GSTO2, GSTP1, GSTT1, GSTT2, GSTZ1, MGST1, MGST2, MGST3, PTGESMethyl transferasesAS3MT, ASMT, COMT, GAMT, GNMT, HNMT, INMT, NNMT, PNMT, TPMTN-Acetyl transferasesAANAT, ACSL1, ACSL3, ACSL4, ACSM1, ACSM2B, ACSM3, GLYAT, NAT1, NAT2, NAA20, SAT1ThioltransferaseGLRXSulfotransferasesSULT1A1, SULT1A2, SULT1A3, SULT1B1, SULT1C1, SULT1C2, SULT1C3, SULT1C4, SULT1E1, SULT2A1, SULT2B1, SULT4A1, SULT6B1, TST, CHST1, CHST2, CHST3, CHST4, CHST5, CHST6, CHST7, CHST8, CHST9, CHST10, CHST11, CHST12, CHST13, GAL3ST1[^1]

Among these enzymes, CYP2D6, CYP2C9, CYP2C19, and CYP3A4/5 are the most relevant in the pharmacogenetics of CNS drugs [@b0075], [@b0555] ([Table 27.1](#t0010){ref-type="table"}). Approximately 18% of neuroleptics are major substrates of CYP1A2 enzymes, 40% of CYP2D6, and 23% of CYP3A4; 24% of antidepressants are major substrates of CYP1A2 enzymes, 5% of CYP2B6, 38% of CYP2C19, 85% of CYP2D6, and 38% of CYP3A4; 7% of benzodiazepines are major substrates of CYP2C19 enzymes, 20% of CYP2D6, and 95% of CYP3A4 [@b0075], [@b0555]. Most CYP enzymes exhibit ontogenic-, age-, sex-, circadian-, and ethnic-related differences [@b0560].

In dementia, as in any other CNS disorder, CYP genomics is a very important issue, since in practice more than 90% of patients with dementia are daily consumers of psychotropics. Furthermore, some acetylcholinesterase inhibitors (the most prescribed antidementia drugs worldwide) are metabolized via CYP enzymes ([Table 27.1](#t0010){ref-type="table"}). Most CYP enzymes display highly significant ethnic differences, indicating that the enzymatic capacity of these proteins varies depending upon the polymorphic variants present in their coding CYP genes.

The practical consequence of this genetic variation is that the same drug can be differentially metabolized according to the genetic profile of each subject, and that, if an individual's pharmacogenomic profile is known, his/her pharmacodynamic response is potentially predictable. This is the cornerstone of pharmacogenetics. In this regard, the *CYP2D6*, *CYP2C19*, *CYP2C9*, and *CYP3A4*/*5* genes and their respective protein products deserve special consideration.

### 27.7.3.1. CYP2D6 {#s0140}

*CYP2D6* is a 4.38 kb gene with 9 exons mapped on 22q13.2. Four RNA transcripts of 1190--1684 bp are expressed in the brain, liver, spleen, and reproductive system, where 4 major proteins of 48--55 kDa (439--494 aa) are identified. It is a transport enzyme of the cytochrome P450 subfamily IID or multigenic cytochrome P450 superfamily of mixed-function monooxygenases. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. CYP2D6 localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs, and more than 60% of current psychotropics. Its substrates include debrisoquine, an adrenergic-blocking drug; sparteine and propafenone, both antiarrhythmic drugs; and amitryptiline, an antidepressant. CYP2D6 is highly polymorphic in the population.

There are 141 *CYP2D6* allelic variants, of which -100C \> T, -1023C \> T, -1659G \> A, -1707delT, -1846G \> A, -2549delA, -2613-2615delAGA, -2850C \> T, -2988G \> A, and -3183G \> A represent the ten most important [@b0565], [@b0570], [@b0575]. Different alleles result in the extensive, intermediate, poor, and ultrarapid metabolizer phenotypes, characterized by normal, intermediate, decreased, and multiplied ability to metabolize the enzyme's substrates, respectively. The hepatic cytochrome P450 system is responsible for the first phase in the metabolism and elimination of numerous endogenous and exogenous molecules and ingested chemicals. P450 enzymes convert these substances into electrophilic intermediates, which are then conjugated by phase II enzymes (e.g., UDP glucuronosyltransferases, N-acetyltransferases) to hydrophilic derivatives that can be excreted. According to the database of the *World Guide for Drug Use and Pharmacogenomics* [@b0565], 982 drugs are *CYP2D6*-related: 371 are substrates, more than 300 are inhibitors, and 18 are CYP2D6 inducers.

In healthy subjects, extensive metabolizers (EMs) account for 55.71% of the population; intermediate metabolizers (IMs) account for 34.7%; poor metabolizers (PMs), 2.28%; and ultrarapid metabolizers (UMs), 7.31%. Remarkable worldwide interethnic differences exist in the frequency of the PM and UM phenotypes [@b0580], [@b0585], [@b0590]. On average, approximately 6.28% of the world's population belongs to the PM category. Europeans (7.86%), Polynesians (7.27%), and Africans (6.73%) show the highest rate of PMs, whereas Orientals (0.94%) show the lowest [@b0580]. The frequency of PMs among Middle Eastern populations, Asians, and Americans is in the range of 2--3%. *CYP2D6* gene duplications are relatively infrequent among Northern Europeans, but in East Africa the frequency of alleles with duplication of *CYP2D6* is as high as 29% [@b0595]. In Europe, there is a North--South gradient in the frequency of PMs (6--12% of PMs in Southern European countries, and 2--3% of PMs in Northern latitudes) [@b0555].

In AD, EMs, IMs, PMs, and UMs are 56.38%, 27.66%, 7.45%, and 8.51%, respectively, and in vascular dementia, they are, respectively, 52.81%, 34.83%, 6.74%, and 5.62% ([Figure 27.3](#f0015){ref-type="fig"} ). There is an accumulation of AD-related risk genes in PMs and UMs. EMs and IMs are the best responders, and PMs and UMs are the worst responders to a combination therapy of cholinesterase inhibitors, neuroprotectants, and vasoactive substances. The pharmacogenetic response in AD appears to depend on the networking activity of genes involved in drug metabolism and genes involved in AD pathogenesis [@b0035], [@b0060], [@b0075], [@b0080], [@b0110], [@b0115], [@b0120], [@b0125], [@b0130], [@b0135], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295]. Figure 27.3Distribution and frequency of *CYP2D6* phenotypes in AD and vascular dementia.EM---extensive metabolizer; IM---intermediate metabolizer; PM---poor metabolizer; UM---ultrarapid metabolizer.*Source: Adapted from Cacabelos*[@b0090].

### 27.7.3.2. CYP2C9 {#s0145}

*CYP2C9* is a gene (50.71 kb) with 9 exons mapped on 10q24. An RNA transcript of 1860 bp is mainly expressed in hepatocytes, where a protein of 55.63 kDa (490 aa) can be identified. More than 600 drugs are *CYP2C9*-related: 311 act as substrates (177 major, 134 minor); 375, as inhibitors (92 weak, 181 moderate, and 102 strong); and 41 as inducers of the CYP2C9 enzyme [@b0565]. There are 481 *CYP2C9* SNPs. By phenotype ([Figure 27.4](#f0020){ref-type="fig"} ), in the control population, PMs represent 7.04%, IMs 32.39%, and EMs 60.56%. In AD, PMs, IMs, and EMs are 6.45%, 37.64%, and 55.91%, respectively, and in vascular dementia they are 3.61%, 28.92%, and 67.47%, respectively [@b0090] ([Figure 27.4](#f0020){ref-type="fig"}).Figure 27.4Distribution and frequency of *CYP2C9* phenotypes in AD and vascular dementia.EM---extensive metabolizer; IM---intermediate metabolizer; PM---poor metabolizer.*Source: Adapted from Cacabelos*[@b0090].

### 27.7.3.3. CYP2C19 {#s0150}

*CYP2C19* is a gene (90.21 kb) with 9 exons mapped on 10q24.1q24.3. RNA transcripts of 1901 bp, 2395 bp, and 1417 bp are expressed in liver cells, where a protein of 55.93 kDa (490 aa) has been identified. Nearly 500 drugs are *CYP2C19*-related, with 281 acting as substrates (151 major, 130 minor), 263 as inhibitors (72 weak, 127 moderate, and 64 strong), and 23 as inducers of the CYP2C19 enzyme [@b0565]. About 541 SNPs have been detected in the *CYP2C19* gene. The frequencies of the three major *CYP2C19* geno-phenotypes in the control population are *CYP2C19-\*1/\*1*-EMs, 68.54%; *CYP2C19-\*1/\*2*-IMs, 30.05%; and *CYP2C19-\*2/\*2*-PMs, 1.41%. EMs, IMs, and PMs account for 69.89%, 30.11%, and 0%, respectively, in AD, and 66.27%, 30.12%, and 3.61%, respectively, in vascular dementia [@b0090] ([Figure 27.5](#f0025){ref-type="fig"} ).Figure 27.5Distribution and frequency of *CYP2C19* pheno- genotypes in AD and vascular dementia.EM---extensive metabolizer; IM---intermediate metabolizer; PM---poor metabolizer.*Source: Adapted from Cacabelos*[@b0090].

### 27.7.3.4. CYP3A4/5 {#s0155}

*CYP3A4* is a gene (27.2 kb) with 13 exons mapped on 7q21.1. RNA transcripts of 2153 bp, 651 bp, 564 bp, 2318 bp, and 2519 bp are expressed in intestine, liver, prostate, and other tissues, where four protein variants of 57.34 kDa (503 aa), 17.29 kDa (153 aa), 40.39 kDa (353 aa), and 47.99 kDa (420 aa) have been identified. The human *CYP3A* locus contains the three *CYP3A* genes (*CYP3A4*, *CYP3A5,* and *CYP3A7*), three pseudogenes, and a novel *CYP3A* gene termed *CYP3A43*. The gene encodes a putative protein with 71.5--75.8% identity with the other CYP3A proteins. The predominant hepatic form is CYP3A4, but CYP3A5 contributes significantly to total liver CYP3A activity.

*CYP3A4* metabolizes more than 1900 drugs: 1033 act as substrates (897 major, 136 minor); 696, as inhibitors (118 weak, 437 moderate, and 141 strong); and 241, as inducers of the CYP3A4 enzyme [@b0565]. About 347 SNPs have been identified in the *CYP3A4* gene (*CYP3A4\*1A*: wild-type), 25 of which are of clinical relevance. Concerning *CYP3A4/5* polymorphisms in AD, 82.75% of cases are EMs (*CYP3A5\*3/\*3*), 15.88% are IMs (*CYP3A5\*1/\*3*), and 1.37% are UMs (*CYP3A5\*1/\*1*). Unlike other human P450s (*CYP2D6*, *CYP2C19*), there is no evidence of a "null" allele for *CYP3A4* [@b0565].

### 27.7.3.5. CYP Clustering {#s0160}

The construction of a genetic map integrating the most prevalent *CYP2D6*+*CYP2C19*+*CYP2C9* polymorphic variants in a trigenic cluster yields 82 different haplotype-like profiles. The most frequent trigenic genotypes in the AD population are *\*1\*1-\*1\*1-\*1\*1* (25.70%), *\*1\*1-\*1\*2-\*1\*2* (10.66%), *\*1\*1-\*1\*1-\*1\*1* (10.45%), *\*1\*4-\*1\*1-\*1\*1* (8.09%), *\*1\*4-\*1\*2-\*1\*1* (4.91%), *\*1\*4-\*1\*1-\*1\*2* (4.65%), and *\*1\*1-\*1\*3-\*1\*3* (4.33%). These 82 trigenic genotypes represent 36 different pharmacogenetic phenotypes.

According to these trigenic clusters, only 26.51% of patients show a pure 3EM phenotype, 15.29% are 2EM1IM, 2.04% are pure 3IM, 0% are pure 3PM, and 0% are 1UM2PM (the worst possible phenotype). This implies that only one-quarter of the population normally process the drugs that are metabolized via CYP2D6, CYP2C9, and CYP2C19 (approximately 60% of the drugs in current use) [@b0060]. Taking into consideration the data available, it might be inferred that at least 20--30% of the AD population may exhibit an abnormal metabolism of cholinesterase inhibitors and/or other drugs that undergo oxidation via *CYP2D6*-related enzymes.

Approximately 50% of this population cluster shows an ultrarapid metabolism, requiring higher doses of cholinesterase inhibitors in order to reach a therapeutic threshold. The other 50% of the cluster exhibit a poor metabolism, displaying potential adverse events at low doses. If we take into account that approximately 60--70% of therapeutic outcomes depend on pharmacogenomic criteria (e.g., pathogenic mechanisms associated with AD-related genes), it can be postulated that pharmacogenetic and pharmacogenomic factors are responsible for 75--85% of therapeutic response (efficacy) in AD patients treated with conventional drugs [@b0060], [@b0075], [@b0080], [@b0085], [@b0090], [@b0110], [@b0115], [@b0120], [@b0125], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295].

27.7.4. Drug Transporters {#s0165}
-------------------------

ABC genes---especially *ABCB1* (ATP-binding cassette, subfamily B, member 1P-glycoprotein-1, P-gp1, Multidrug Resistance 1, MDR (17q21.12), *ABCC1* (9q31.1), *ABCG2* (White121q22.3), and other genes of this family---encode proteins that are essential for drug metabolism and transport. The multidrug efflux transporters P-gp, the multidrug resistance-associated protein 4 (MRP4), and the breast cancer resistance-protein (BCRP), located on endothelial cells lining the brain vasculature, play important roles in limiting the movement of substances into the brain and in enhancing their efflux from the brain.

Transporters also cooperate with phase I/phase II metabolism enzymes by eliminating drug metabolites. Their major features are their capacity to recognize drugs belonging to unrelated pharmacological classes and their redundancy, by which a single molecule can act as a substrate for different transporters. This ensures efficient neuroprotection against xenobiotic invasions. The pharmacological induction of ABC gene expression is a mechanism of drug interaction, which may affect substrates of the upregulated transporter; overexpression of MDR transporters confers resistance to anti-cancer agents and CNS drugs [@b0600], [@b0605].

Also of importance for CNS pharmacogenomics are transporters encoded by genes of the solute carrier superfamily (SLC) and solute carrier organic (SLCO) transporter family, which are responsible for the transport of multiple endogenous and exogenous compounds, including folate (*SLC19A1*), urea (*SLC14A1*, *SLC14A2*), monoamines (*SLC29A4*, *SLC22A3*), aminoacids (*SLC1A5*, *SLC3A1*, *SLC7A3*, *SLC7A9*, *SLC38A1*, *SLC38A4*, *SLC38A5*, *SLC38A7*, *SLC43A2*, *SLC45A1*), nucleotides (*SLC29A2*, *SLC29A3*\], fatty acids (*SLC27A1-6*), neurotransmitters (*SLC6A2*\[noradrenaline transporter\]), *SLC6A3*\[dopamine transporter\], *SLC6A4*\[serotonin transporter, SERT\], *SLC6A5*, *SLC6A6*, *SLC6A9*, *SLC6A11*, *SLC6A12*, *SLC6A14*, *SLC6A15*, *SLC6A16*, *SLC6A17*, *SLC6A18*, *SLC6A19*), glutamate (*SLC1A6*, *SLC1A7*), and others [@b0610].

Some organic anion transporters (OAT), which belong to the solute carrier (SLC) 22A family, are also expressed at the BBB, and regulate the excretion of endogenous and exogenous organic anions and cations [@b0615]. The transport of amino acids and di- and tripeptides is mediated by a number of different transporter families, and the bulk of oligopeptide transport is attributable to the activity of members of the *SLC15A* superfamily (peptide transporters 1 and 2 (*SLC15A1*\[PepT1\]) and *SLC15A2*\[PepT2\], and peptide/histidine transporters 1 and 2 (*SLC15A4*\[PHT1\] and *SLC15A3*\[PHT2\]). ABC and SLC transporters expressed at the BBB may cooperate to regulate the passage of different molecules into the brain [@b0620]. Polymorphic variants in ABC and SLC genes may also be associated with pathogenic events in CNS disorders and drug-related safety and efficacy complications [@b0555], [@b0610].

27.7.5. Pleiotropic Activity of *APOE* in Dementia {#s0170}
--------------------------------------------------

*APOE* is the prototypical paradigm of a pleiotropic gene with multifaceted activities in physiological and pathological conditions [@b0080], [@b0110]. ApoE is consistently associated with the amyloid plaque marker for AD. *APOE*-4 may influence AD pathology interacting with APP metabolism and Aβ accumulation, enhancing hyperphosphorylation of tau protein and NFT formation, reducing choline acetyltransferase activity, increasing oxidative processes, modifying inflammation-related neuroimmunotrophic activity and glial activation, altering lipid metabolism, lipid transport, and membrane biosynthesis in sprouting and synaptic remodeling, and inducing neuronal apoptosis [@b0080], [@b0115], [@b0120], [@b0125].

To address the complex misfolding and aggregation that initiates the toxic cascade resulting in AD, Petrlova et al. [@b0130] developed a 2,2,6,6-tetramethylpiperidine-1-oxyl-4-amino-4-carboxylic acid spin-labeled amyloid-β (Aβ) peptide to observe its isoform-dependent interaction with the ApoE protein. Oligomer binding involves the C-terminal domain of ApoE, with ApoE3 reporting a much greater response through this conformational marker. ApoE3 displays a higher affinity and capacity for the toxic Aβ oligomer. ApoE polymorphism and AD risk can largely be attributed to the reduced ability of ApoE4 to function as a clearance vehicle for the toxic form of Aβ. *MAPT* and *APOE* are involved in the pathogenic mechanisms of AD, and both the *MAPT H1/H1* genotype and the *APOE ɛ4* allele lead to a more rapid progression to dementia among MCI subjects, probably mediating an increased rate of amyloid-β and tau brain deposition [@b0135].

The distribution of *APOE* genotypes in the Iberian peninsula is as follows: *APOE-2/2* 0.32%; *APOE-2/3* 7.3%; *APOE-2/4* 1.27%; *APOE-3/3* 71.11%; *APOE-3/4* 18.41%; and *APOE-4/4* 1.59% [@b0090] ([Figure 27.2](#f0010){ref-type="fig"}). These frequencies are very similar in Europe and in other Western societies. There is a clear accumulation of *APOE-4* carriers among patients with AD (*APOE-3/4* 30.30%, *APOE-4/4* 6.06%) and vascular dementia (*APOE-3/4* 35.85%, *APOE-4/4* 6.57%) as compared to controls ([Figure 27.2](#f0010){ref-type="fig"}). Different *APOE* genotypes confer specific phenotypic profiles to AD patients [@b0075], [@b0080], [@b0110]. Some of these profiles may add risk or benefit when patients are treated with conventional drugs, and in many instances the clinical phenotype demands the administration of additional drugs that increase the complexity of therapeutic protocols.

From studies designed to define *APOE*-related AD phenotypes [@b0035], [@b0060], [@b0115], [@b0120], [@b0125], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295], several conclusions can be drawn, which are shown in [Box 27.2](#x0010){ref-type="boxed-text"}. These 20 major phenotypic features clearly illustrate the biological disadvantage of *APOE-4* homozygotes and the potential consequences that these patients may experience when they receive pharmacological treatment for AD and/or concomitant pathologies [@b0035], [@b0060], [@b0115], [@b0120], [@b0125], [@b0140], [@b0265], [@b0270], [@b0275], [@b0280], [@b0285], [@b0290], [@b0295].Box 27.2Key Conclusions Regarding APOE-Related AD Phenotypes1.The age at onset is 5--10 years earlier in approximately 80% of AD cases harboring the *APOE-4/4* genotype.2.The serum levels of ApoE are lowest in *APOE-4/4*, intermediate in *APOE-3/3* and *APOE-3/4*, and highest in *APOE-2/3* and *APOE-2/4*.3.Serum cholesterol levels are higher in *APOE-4/4* than in other genotypes.4.HDL-cholesterol levels tend to be lower in *APOE-3* homozygotes than in *APOE-4* allele carriers.5.LDL-cholesterol levels are systematically higher in *APOE-4/4* than in any other genotype.6.Triglyceride levels are significantly lower in *APOE-4/4*.7.Nitric oxide levels are slightly lower in *APOE-4/4*.8.Serum and cerebrospinal fluid Aβ levels tend to differ between *APOE-4/4* and the other most frequent genotypes (*APOE-3/3*, *APOE-3/4*).9.Blood histamine levels are dramatically reduced in *APOE-4/4* as compared to the other genotypes.10.Brain atrophy is markedly increased in *APOE-4/4*\>*APOE-3/4*\>*APOE-3/3*.11.Brain mapping activity shows a significant increase in slow wave activity in *APOE-4/4* from the early stages of the disease.12.Brain hemodynamics, as reflected by reduced brain blood flow velocity and increased pulsatility and resistance indices, is significantly worse in *APOE-4/4* (and in *APOE-4* carriers in general, as compared with *APOE-3* carriers); brain hypoperfusion and neocortical oxygenation is also more deficient in *APOE-4* carriers.13.Lymphocyte apoptosis is markedly enhanced in *APOE-4* carriers.14.Cognitive deterioration is faster in *APOE-4/4* patients than in carriers of any other *APOE* genotype.15.In approximately 3--8% of AD cases, some dementia-related metabolic dysfunctions accumulate more in *APOE-4* carriers than in *APOE-3* carriers.16.Some behavioral disturbances, alterations in circadian rhythm patterns, and mood disorders are slightly more frequent in *APOE-4* carriers.17.Aortic and systemic atherosclerosis is more frequent in *APOE-4* carriers.18.Liver metabolism and transaminase activity differ in *APOE-4/4* with respect to other genotypes.19.Hypertension and other cardiovascular risk factors accumulate in *APOE-4* carriers.20.*APOE-4/4* carriers are the poorest responders to conventional drugs.

27.7.6. Pharmacogenomics of Antidementia Drugs {#s0175}
----------------------------------------------

The following list describes the pharmacogenomics of the most common antidementia drugs ([Table 27.1](#t0010){ref-type="table"}).

**Donepezil:** is a centrally active, reversible acetylcholinesterase inhibitor that increases the acetylcholine available for synaptic transmission in the CNS. The therapeutic response of donepezil is influenced by pathogenic gene variants (*APOE*, *CHAT*), as well as mechanistic gene polymorphic variants (*CHAT*, *ACHE*, and *BCHE*). It is a major substrate of CYP2D6, CYP3A4, ACHE, and UGTs; it inhibits ACHE and BCHE; and it is transported by ABCB1 [@b0565].

**Galantamine:** is a reversible and competitive acetylcholinesterase inhibitor leading to increased concentration of acetylcholine at cholinergic synapses. It also modulates nicotinic acetylcholine receptors and may increase glutamate and serotonin levels. *APOE*, *APP*, *ACHE*, *BCHE*, *CHRNA4*, *CHRNA7*, and *CHRNB2* variants may potentially influence galantamine efficacy and safety. Galantamine is a major substrate of CYP2D6, CYP3A4, and UGT1A1, and an inhibitor of ACHE and BCHE [@b0565].

**Rivastigmine:** is a cholinesterase inhibitor that increases acetylcholine in the CNS through reversible inhibition of its hydrolysis by cholinesterase. *APOE*, *APP*, *CHAT*, *ACHE*, *BCHE*, *CHRNA4*, *CHRNB2*, and *MAPT* variants may affect its pharmacokinetics and pharmacodynamics [@b0565].

**Tacrine:** is the first FDA-approved antidementia drug. Its use was stopped due to hepatotoxicity. Tacrine is a cholinesterase inhibitor that elevates acetylcholine in the cerebral cortex by slowing degradation of acetylcholine. *ACHE*, *BCHE*, *CHRNA4*, *CHRNB2*, *APOE*, *MTHFR*, *CES1*, *LEPR*, *GSTM1*, and *GSTT1* variants may affect its therapeutic and toxic effects. Tacrine is a major substrate of CYP1A2 and CYP3A4, a minor substrate of CYP2D6, and is transported via SCN1A. It is an inhibitor of ACHE, BCHE, and CYP1A2 [@b0565].

**Memantine:** is an N-Methyl-D-Aspartate (NMDA) receptor antagonist that binds preferentially to NMDA receptor-operated cation channels. It may act by blocking the actions of glutamate, mediated in part by NMDA receptors, and it is also an antagonist of GRIN2A, GRIN2B, GRIN3A, HTR3A, and CHRFAM7A. Several pathogenic (*APOE*, *PSEN1*, *MAPT*) and mechanistic gene variants (*GRIN2A*, *GRIN2B*, *GRIN3A*, *HTR3A*, *CHRFAM7A*) may influence its therapeutic effects. Memantine is a strong inhibitor of CYP2B6 and CYP2D6, and a weak inhibitor of CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 [@b0565].

27.7.7. Multifactorial Therapy {#s0180}
------------------------------

Some studies using a multifactorial approach also have shown that diverse pharmacogenomic factors may influence efficacy and safety. In one of these studies [@b0075], [@b0290], patients with dementia received the following for three months: a multifactorial therapy integrated by CDP-choline (500 mg/day, p.o.), Nicergoline (5 mg/day, p.o.), Sardilipin (E-SAR-94010) (LipoEsar^®^)(250 mg, t.i.d.), and Animon Complex^®^ (2 capsules/day)---a nutraceutical compound integrated by a purified extract of *Chenopodium quinoa* (250 mg), ferrous sulphate (38.1 mg equivalent to 14 mg of iron), folic acid (200 μg), and vitamin B~12~ (1 μg) per capsule (RGS: 26.06671/C).

Patients with chronic deficiencies of iron (\<35 μg/mL), folic acid (\<2.5 ng/mL), or vitamin B~12~ (\<150 pg/mL) received an additional supplement of iron (80 mg/day), folic acid (5 mg/day), and B complex vitamins (B~1~, 15 mg/day; B~2~, 15 mg/day; B~6~, 10 mg/day; B~12~, 10 μg/day; nicotinamide, 50 mg/day), respectively, to maintain stable levels of serum iron (50--150 μg/mL), folic acid (5--20 ng/mL) and vitamin B~12~ levels (500--1000 pg/mL) in order to avoid the negative influence of all these metabolic factors on cognition. Patients with hypertension (\>150/85 mmHg) received Enalapril (20 mg/day).

The frequency of *APOE* genotypes was *APOE-2/3,* 7.97%; *APOE-2/4*, 1.18%; *APOE-3*, 58.95%; *APOE-3/4*, 27.32%; and *APOE-4/4*, 4.58%. Cognitive function (as assessed by MMSE); 20.51 ± 6.51 vs. 21.45 ± 6.95, p \< 0.0000000001; ADAS-Cog, 22.94 ± 13.87 vs. 21.23 ± 12.84, p \< 0.0001; ADAS-Non-Cog, 5.26 ± 4.18 vs. 4.15 ± 3.63, p \< 0.0000000001; ADAS-Total, 27.12 ± 16.93 vs. 24.28 ± 15.06, p \< 0.00009) improved after treatment. Mood (HAM-A, 11.35 ± 5.44 vs. 9.79 ± 4.33, p \< 0.0000000001; HAM-D, 10.14 ± 5.23 vs. 8.59 ± 4.30, p \< 0.0000000001) also improved. Glucose levels did not change.

Total cholesterol levels (224.78 ± 45.53 vs. 203.64 ± 39.69 mg/dL, p \< 0.0000000001), HDL-cholesterol levels (54.11 ± 14.54 vs. 52.54 ± 14.86 mg/dL, p \< 0.0001), and LDL-cholesterol levels (148.15 ± 39.13 vs. 128.89 ± 34.83 mg/dL, p \< 0.0000000001) were significantly reduced. Folate (7.07 ± 3.61 vs. 18.14 ± 4.23 ng/mL, p \< 0.000000001) and vitamin B~12~ levels (459.65 ± 205.80 vs. 689.78 ± 338.82 pg/mL, p \< 0.000000001) also increased, and both TSH and T~4~ levels remained unchanged after treatment. The response rate in terms of cognitive improvement was as follows: 59.74% responders (RRs), 24.44% nonresponders (NRs), and 15.82% stable responders (SRs) (no change in MMSE score after three months of treatment). The response rate in cholesterol levels was very similar: 57.78% RRs, 28.50% NRs, and 13.72% SRs [@b0075].

### 27.7.7.1. APOE-Related Cognitive Function Changes {#s0185}

In this study, the basal MMSE score differed in *APOE-2/3* carriers with respect to *APOE-2/4* (p \< 0.02), *APOE-3/4* (p \< 0.004), and *APOE-4/4* (p \< 0.0009), in *APOE-3/3* vs. *APOE-3/4* (p \< 0.0005), and in *APOE-3/3* vs. *APOE-4/4* (p \< 0.002). The best responders were *APOE-3/3* (p \< 0.0000000001) \>*APOE-3/4* (p \< 0.00001) \>*APOE-4/4* carriers (p \< 0.05). Patients harboring the *APOE-2/3* and *APOE-2/4* genotypes did not show any significant improvement. The response rate by genotype was the following: *APOE-2/3*: 44.26% RRs, 36.07% NRs, 19.67% SRs; *APOE-2/4*: 55.56% RRs, 44.44% NRs, 0.0% SRs; *APOE-3/3*: 63.42% RRs, 21.06% NRs, 15.52% SRs; *APOE-3/4*: 56.94% RRs, 27.75% NRs, 15.31% SRs; and *APOE-4/4*: 51.43% RRs, 28.57% NRs, 20.00% SRs [@b0075] ([Figure 27.6](#f0030){ref-type="fig"}, [Figure 27.7](#f0035){ref-type="fig"} ).Figure 27.6*APOE*-related cognitive performance in response to multifactorial therapy in patients with dementia.Tb---basal MMSE score prior to treatment; Tt---MMSE score after 3 months treatment in total sample. E2/3b---basal MMSE score in *APOE-2/3* carriers; E2/3t---MMSE score after treatment in *APOE-2/3* carriers; E2/4b---basal MMSE score in *APOE-2/4* carriers; E2/4t---MMSE score after treatment in *APOE-2/4* carriers; E3/3b---basal MMSE score in *APOE-3/3* carriers; E3/3t---MMSE score after treatment in *APOE-3/3* carriers; E3/4b basal MMSE score in *APOE-3/4* carriers; E3/4t---MMSE score after treatment in *APOE-3/4* carriers; E4/4b---basal MMSE score in *APOE-4/4* carriers; E4/4---MMSE score after treatment in *APOE-4/4* carriers.*Source: Adapted from Cacabelos et al.*[@b0075].Figure 27.7*APOE*-related cognitive response rate in patients with dementia treated with multifactorial therapy.

### 27.7.7.2. APOE-Related Changes in Blood Pressure Values {#s0190}

Systolic blood pressure (SBP) was significantly reduced in patients with the *APOE-3/3* (p \< 0.00007) and *APOE-3/4* genotypes (p \< 0.01), and diastolic blood pressure exhibited a similar pattern (*APOE-3/3*, p \< 0.005; *APOE-3/4*, p \< 0.01), with no changes in either SBP or DBP in *APOE-2/3*, *APOE-2/4*, and *APOE-4/4* carriers [@b0075].

### 27.7.7.3. APOE-Related Blood Lipid Response to Sardilipin {#s0195}

Basal cholesterol levels were significantly different in patients with the *APOE-2/3* genotype vs. *APOE-3/3* (p \< 0.007), vs. *APOE-3/4* (p \< 0.001), vs. *APOE-4/4* (p \< 0.00002); *APOE-2/4* vs. *APOE-4/4* (p \< 0.01); *APOE-3/3* vs. *APOE-4/4* (p \< 0.005); and *APOE-3/4* vs. *APOE-4/4* (p \< 0.01).

The highest cholesterol levels were seen in *APOE-4/4*\> *APOE-3/4*\> *APOE-3/3.* All patients showed a clear reduction in cholesterol levels after treatment with Sardilipin. This was particularly significant in *APOE-3/3* (p \< 0.0000000001) \> *APOE-3/4* (p \< 0.00000008) \> *APOE-4/4* (p \< 0.002) \> *APOE-2/3* (p \< 0.02) \> *APOE-2/4* carriers (p: 0.26). The response rate by genotype was as follows: *APOE-2/3*: 63.93% RRs, 29.51% NRs, 6.56% SRs; *APOE-2/4*: 44.44% RRs, 22.22% NRs, 33.34% SRs; *APOE-3/3*: 54.32% RRs, 28.16% NRs, 17.52% SRs; *APOE-3/4*: 53.59% RRs, 31.58% NRs, 14.83% SRs; *APOE-4/4*: 65.71% RRs, 20.00% NRs, 14.29% SRs [@b0075].

HDL-cholesterol levels significantly decreased in *APOE-3/3* (p \< 0.001) \> *APOE-3/4* (p \< 0.05), with no significant changes in patients with other genotypes. In contrast, LDL-cholesterol levels showed changes identical to those observed in total cholesterol, with similar differences among genotypes at baseline and almost identical decreased levels after treatment (*APOE-3/3*, p \> 0.0000000001 \>*APOE-3/4*, p \< 0.00001 \>*APOE-2/3*, p \< 0.0004 \>*APOE-4/4*, p \< 0.001 \>*APOE-2/4*, p:0.31) [@b0075].

Sardilipin (E-SAR-94010, LipoEsar^®^, LipoSea^®^) is a natural product extracted from the marine species *Sardina pilchardus* by means of nondenaturing biotechnological procedures. The main chemical compounds of LipoEsar^®^ are lipoproteins (60--80%), whose micelle structure probably mimics that of physiological lipoproteins involved in lipid metabolism. In preclinical studies, Sardilipinhas been shown to be effective in:1.Reducing blood cholesterol (CHO), triglyceride (TG), uric acid (UA), and glucose (Glu) levels, as well as liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity.2.Enhancing immunological function by regulating both lymphocyte and microglia activity.3.Inducing antioxidant effects mediated by superoxide dismutase activity.4.Improving cognitive function [@b0075].

According to these results, it appears that the therapeutic response of patients with dyslipidemia to Sardilipin is *APOE*-related. The best responders were patients with *APOE-3/3* \>*APOE-3/4* \>*APOE-4/4*. Patients with the other *APOE* genotypes (*2/2*, *2/3*, *2/4*) did not show any hypolipidemic response to this novel compound. In patients with dementia, the effects of Sardilipin were very similar to those observed in patients with chronic dyslipidemia, suggesting that the lipid-lowering properties of Sardilipin are *APOE*-dependent [@b0075] ([Figure 27.8](#f0040){ref-type="fig"} ).Figure 27.8*APOE*-related total cholesterol levels in response to multifactorial therapy in patients with dementia.Tb---basal cholesterol levels prior to treatment; Tt---cholesterol levels after 3 months treatment in total sample. E2/3b---basal cholesterol levels in *APOE-2/3* carriers; E2/3t---total cholesterol levels after treatment in *APOE-2/3* carriers; E2/4b---basal cholesterol levels in *APOE-2/4* carriers; E2/4t---total cholesterol levels after treatment in *APOE-2/4* carriers; E3/3b---basal cholesterol levels in *APOE-3/3* carriers; E3/3t---total cholesterol levels after treatment in *APOE-3/3* carriers; E3/4b---basal cholesterol levels in *APOE-3/4* carriers; E3/4t---total cholesterol levels after treatment in *APOE-3/4* carriers; E4/4b---basal cholesterol levels in *APOE-4/4* carriers; E4/4---total cholesterol levels after treatment in *APOE-4/4* carriers.*Source: Adapted from Cacabelos et al.*[@b0075].

27.8. Future Perspective {#s0200}
========================

To make AD a global health priority in the coming years, conceptual and procedural changes are needed on several grounds, such as (1) political, administrative, economic, legal, ethical, industrial, regulatory and educational issues; (2) novel biomarkers (genomics, proteomics, molecular neuroimaging) as diagnostic aids; (3) innovative therapeutics; (4) pharmacogenomics in clinical practice to optimize therapeutics; and (5) selective preventive plans for the population at risk.

There is disharmony concerning the public and governmental interest in dementia and its social, medical, and economic implications. The diagnosis and management of dementia is dissimilar in Europe, North America, Latin America, Asia, Africa, and Oceania. The economic/cultural status of each country (developed versus developing), the particular epidemiology of aging and dementia in each latitude, national standards of education, health priorities (infectious diseases versus degenerative diseases), and the quality and efficiency of medical services are conditioning factors for investing (or not investing) national resources in dementia as a health priority.

Educational programs, international guidelines, and consensus protocols for the management of dementia are necessary for global harmonization, for professionals from different countries to speak the same conceptual language, and to improve cost-effectiveness ratios [@b0625], [@b0630], [@b0635], [@b0640]. There are many legal issues (e.g., informed consent, lawsuit, testament, tutorship) and ethical issues (e.g., clinical trials, use of genetic information, institutionalization) that deserve more attention in order to humanize the end of life in the very frail conditions under which demented patients survive.

The updating of regulatory issues is also a matter of deep concern. Regulatory aspects of drug development are not universal, with notable peculiarities in the European Union (EMA), the United States (FDA), and Japan (Koseisho). Because the costs of dementia cannot be fully assumed by more than 60% of the European population, European authorities must take into account this circumstance when health reform is implemented in the coming years [@b0040], [@b0090].

Genomics, transcriptomics, proteomics, and metabolomics will revolutionize medicine in the next decades. Genetic testing is gaining acceptance among physicians and patients in different countries [@b0640], [@b0645], [@b0650], [@b0655], although Americans, Europeans, and Japanese differ notably in their knowledge, beliefs, and attitudes regarding genetic testing for AD [@b0640], [@b0655], [@b0660]. The validation of protocols for genomic screening will contribute to the implementation of structural genomics, functional genomics, and proteomics as diagnostic aids and therapeutic targets [@b0665].

An accurate diagnosis of AD demands the use of reliable biomarkers in routine protocols at a reasonable price [@b0340]. Levels of specific secreted cellular signaling proteins in cerebrospinal fluid or plasma correlate with pathological changes in the AD brain; therefore, proteomic analysis of these levels can be used to discover said biomarkers [@b0705]. It is likely that the best biomarkers result from a combination of genomic, transcriptomic, and proteomic analyses of body fluids. The measurement of these biomarkers correlates with brain imaging markers and cognitive performance [@b0365], [@b0370], [@b0375].

New initiatives for the prevention of dementia (global versus selective prevention) will also emerge [@b0675], together with new insights into the role of nutrition and nutrigenomics in brain function and neurodegeneration [@b0295], [@b0680]. In terms of prevention, it must be taken into consideration that neuronal death and Aβ accumulation starts many years before the onset of the disease, and that preventive strategies should be selective to protect the population at risk. For this purpose, accurate biomarkers are essential, and surrogate markers are needed to facilitate primary prevention.

Without doubt, the highest priority for the coming decade will be an intense search for novel therapeutic options in the form of both symptomatic treatments and preventive strategies. Past failures must be studied by researchers and the pharmaceutical industry in order to avoid unnecessary expenses in redundant trials that lead nowhere. Combination treatments require further evaluation and more sophisticated strategies than dual combinations [@b0685], [@b0690]. The administration of psychotropic drugs to demented patients should be reduced and predicted with pharmacogenetic markers to minimize side effects, cerebrovascular risk, and cognitive deterioration.

Priority areas for pharmacogenetic research are the prediction of serious adverse drug reactions (ADRs) and the determination of efficacy variation [@b0695]. Both are necessary in CNS disorders and dementia to cope with efficacy and safety issues associated with current psychotropics and antidementia drugs, as well as new CNS drugs. With regard to the future of pharmacogenomics as a practical discipline, several issues should be addressed:•The education of physicians in medical genomics and pharmacogenomics is fundamental (less than 2% of clinicians are familiar with genomic science)•Genomic screening of gene clusters involved in pharmacogenomic outcomes must become a clinical routine (without genetic testing, there is no pharmacogenetics)•Each patient must be a carrier of a pharmacogenetic card [@b0700] indicating what kind of drugs he/she can take and which medications he/she should avoid•Regulatory agencies should request pharmacogenetic data from the pharmaceutical industry when applying for drug approval•Pharmacogenetic data must be incorporated into patient information leaflets and the pharmaceutical *vade mecum*•New guidelines for daily praxis, such as those given in the *World Guide for Drug Use and Pharmacogenomics* [@b0565], will promote understanding of the relationship between drugs and genes to make drug prescription truly personalized

27.9. Conclusion {#s0205}
================

AD is a major health problem that comes with a high cost to society. As a clinical entity, AD is a polygenic/complex disorder in which many different gene clusters may be involved. Most genes screened to date belong to different proteomic and metabolomic pathways that potentially affect AD pathogenesis, represented by accumulation of Aβ deposits in senile plaques, intracellular NFTs with hyperphosphorylated tau, and neuronal loss.

The presence of the *APOE-4* allele of the apolipoprotein E gene seems to be a major risk factor for both degenerative and vascular dementia, and *APOE* variants are directly involved in AD pathogenesis at multiple levels. Specific biomarkers (structural and functional genomic markers, proteomic markers in body fluids, neuroimaging markers) are needed for an accurate AD diagnosis. Current pharmacological treatment of AD with cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine is not cost-effective; moreover, the overuse of psychotropic drugs in patients with dementia contributes to deteriorating cognitive and psychomotor functions.

Old treatments addressed memory impairment. New treatments are oriented to halting disease progression by interfering with Aβ accumulation, NFT formation, oxidative stress, neuroinflammation, and cerebrovascular damage. Over the past few years diverse candidate drugs have been investigated in AD models, but not one has reached the market. Since only 25--30% of the population is an extensive metabolizer for drugs metabolized via CYP2D6, CYP2C9, and CYP2C19 enzymes, it seems reasonable to use pharmacogenomic procedures as a way to optimize AD therapeutics, thus reducing ADRs and unnecessary costs. The therapeutic response to conventional drugs in patients with AD is genotype-specific, with *CYP2D6*-PMs, *CYP2D6*-UMs, and *APOE-4/4* carriers shown to be the worst responders. *APOE* and *CYP2D6* may cooperate, as pleiotropic genes, in the metabolism of drugs and hepatic function.

If we know the pharmacogenomic profiles of patients who require treatment with antidementia drugs and/or psychotropic drugs currently in use, we may be able to achieve the following benefits:•Identifying candidate patients with the ideal genomic profile to receive a particular drug•Adapting the dose in more than 90% of cases according to the condition of EM, IM, PM, or UM, which will limit the occurrence of direct side effects in 30--50% of cases•Reducing drug interactions by 30--50% (avoiding the administration of inhibitors or inducers able to modify the normal enzymatic activity on a particular substrate)•Enhancing efficacy•Eliminating unnecessary costs (\>30% of pharmaceutical direct costs) deriving from the consequences of inappropriate drug selection and overmedication to mitigate ADRs [@b0090]

Appendix A {#s0210}
==========

Selected Genes Potentially Associated with Alzheimer's DiseaseLocusSize (Kb)SymbolTitle/GeneOMIMOther Related Diseases1p13.152.32NGFNerve growth factor (beta polypeptide)162030Hereditary sensory and autonomic neuropathy type V, allergic rhinitis1p13.35.95GSTM1Glutathione S-transferase mu 1138350Cancer1p13.37.11GSTM3Glutathione S-transferase mu 3 (brain)138390Cancer1p13.320.38CSF1Colony-stimulating factor 1 (macrophage)1204201p13-p1220.94HMGCS23-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial)600234HMG-CoA synthase-2 deficiency1p21232.03COL11A1Collagen, type XI, alpha 1120280Fibrochondrogenesis, Marshall syndrome, Stickler syndrome type II, lumbar disc herniation1p21.3-p13.188.38SORT1Sortilin 16024581p22.218.49GBP2Guanylate binding protein 2, interferon-inducible6004121p31.344.38TM2D1TM2-domain containing 16100801p32134.20ERI3ERI1 exoribonuclease family member 36099171p32.337.62DHCR2424-dehydrocholesterol reductase606418Desmosterolosis1p32.3204.31ZFYVE9Zinc finger, FYVE-domain containing 96037551p3485.79LRP8Low-density lipoprotein receptor-related protein 8, apolipoprotein e receptor602600Myocardial infarction, major depressive disorder1p34.334.93LCKLymphocyte-specific protein tyrosine kinase153390SCID due to LCK deficiency1p36.1128.30ECE1Endothelin-converting enzyme 1600423Hirschsprung disease, cardiac defects, autonomic dysfunction, essential hypertension1p36.13-q31.33.81APH1AAPH1A gamma secretase subunit provided6076291p36.1-p34115.01HSPG2Heparan sulfate proteoglycan 2142461Dyssegmental dysplasia Silverman-Handmaker type, Schwartz-Jampel syndrome type 1, tardive dyskinesia1p36.2212.87TARDBPTAR DNA binding protein605078Amyotrophic lateral sclerosis 10 with or without FTD, frontotemporal lobar degeneration TARDBP-related1p36.383.64TP73Tumor protein p73601990Neuroblastoma1p36.320.37MTHFRMethylenetetrahydrofolate reductase (NAD(P)H)607093Homocystinuria due to MTHFR deficiency, neural tube defects, schizophrenia, thromboembolism, occlusive vascular disease, colon cancer, acute leukemia1p36-p3514.28HTR65-Hydroxytryptamine (serotonin) receptor 6, G protein-coupled6011091q2135.76CTSSCathepsin S1168451q21N/AAD13Alzheimer disease 136111521q213.64S100A1S100 calcium binding protein A1176940Cardiomyopathies1q21.311.55FAM63AFamily with sequence similarity 63, member AN/A1q21.312.10CHRNB2Cholinergic receptor, nicotinic, beta 2 (neuronal)118507Nocturnal frontal lobe epilepsy 31q21-q2266.10NTRK1Neurotrophic tyrosine kinase, receptor, type 1191315Insensitivity to pain with anhidrosis, medullary thyroid carcinoma, self-mutilating behavior, mental retardation1q21-q231.05APCSAmyloid P component, serum104770Secondary amyloidosis1q2257.51LMNALamin A/C150330Emery-Dreifuss muscular dystrophy 2, Emery-Dreifuss muscular dystrophy 3, familial partial lipodystrophy 2, muscular dystrophy, limb girdle muscular dystrophy type 1B, dilated cardiomyopathy 1A, Charcot-Marie-Tooth disease type 2B1, Hutchinson-Gilford progeria syndrome, heart-hand syndrome of Slovenian type, Malouf syndrome, mandibuloacral dysplasia, lethal restrictive dermopathy1q2211.92FDPSFarnesyl diphosphate synthase1346291q22-q2315.68NCSTNNicastrin605254Acne inversa 11q22-q236.72USF1Upstream transcription factor 1191523Hyperlipidemia1q233.95FCER1GFc fragment of IgE, high-affinity I, receptor forgamma polypeptide1471391q23.22.30CRPC-reactive protein, pentraxin-related provided1232601q24.2206.52POU2F1POU class 2 homeobox 11641751q2564.97SOAT1Sterol O-acyltransferase 11026421q25N/AAD14Alzheimer disease 146111541q25.2-q25.38.62PTGS2Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)6002621q31-q324.89IL10Interleukin 10124092Rheumatoid arthritis1q31-q4225.53PSEN2Presenilin 2 (Alzheimer disease 4)600759Dilated cardiomyopathy 1V1q3295.63CFHComplement factor H134370Hemolytic-uremic syndrome, chronic hypocomplementemic nephropathy, basal laminar drusen, complement factor H deficiency, macular degeneration 41q32145.64CR1Complement component (3b/4b) receptor 1 (Knops blood group)120620CR1 deficiency, systemic lupus erythematosus1q32-q4148.77HSD11B1Hydroxysteroid (11-beta) dehydrogenase 1600713Cortisone reductase deficiency 2, obesity, insulin resistance1q41-q4247.41PARP1Poly (ADP-ribose) polymerase 1173870Xeroderma pigmentosum, Fanconi anemia, diabetes type I1q42.212.07AGTAngiotensinogen (serpin peptidase inhibitor, clade A, member 8)106150Renal tubular dysgenesis, non-familial structural atrial fibrillation, inflammatory bowel disease, essential hypertension, preeclampsia1q43108.70MTR5-methyltetrahydrofolate-homocysteine methyltransferase156570Methylcobalamin deficiency type cblG, neural tube defects2p12-p11.11140CTNNA2Catenin (cadherin-associated protein), alpha 21140252p16.378.41RTN4Reticulon 46044752p2168.97LHCGRLuteinizing hormone/choriogonadotropin receptor152790Leydig cell adenoma with precocious puberty, Leydig cell hypoplasia with hypergonadotropic hypogonadism, Leydig cell hypoplasia with pseudohermaphroditism, female luteinizing hormone resistance, male precocious puberty2p22-p2151.91EIF2AK2Eukaryotic translation initiation factor 2-alpha kinase 21768712p2566.53ADAM17ADAM metallopeptidase domain 17603639Neonatal inflammatory skin and bowel disease2q1411.48IL1AInterleukin 1, alpha147760Rheumatoid arthritis2q147.02IL1BInterleukin 1, beta1477202q1459.31BIN1Bridging integrator 1601248Centronuclear myopathy2q14.216.12IL1RNInterleukin 1 receptor antagonist147679Interleukin 1 receptor antagonist deficiency, microvascular complications of diabetes 42q21.188.75KCNIP3Kv channel interacting protein 3, calsenilin6046622q21.21900LRP1BLow-density lipoprotein receptor-related protein 1B6087662q24-q31235.50LRP2Low-density lipoprotein receptor-related protein 2600073Donnai-Barrow syndrome, facio-oculoacousticorenal syndrome2q3475.67CREB1cAMP responsive element binding protein 1123810Angiomatoid fibrous histiocytoma3p21.317.18CCR2Chemokine (C-C motif) receptor 26012673p21.316.07CCR5Chemokine (C-C motif) receptor 5 (gene/pseudogene)601373Insulin-dependent diabetes mellitus 223p25146.51PPARGPeroxisome proliferator-activated receptor gamma601487Carotid intimal medial thickness 1, insulin resistance, lipodystrophy 3, obesity, diabetes type 2, cancer3p26.216.73OGG18-oxoguanine DNA glycosylase601982Renal cell carcinoma3q13.3272.47GSK3BGlycogen synthase kinase 3 beta605004Parkinson disease3q21.388.66RAB7ARAB7A, member RAS oncogene family602298Charcot-Marie-Tooth disease type 2B3q22.132.87TFTransferrin190000Atransferrinemia3q22-q24N/AAD15Alzheimer disease 156111553q25.2104.08MMEMembrane metallo-endopeptidase120520Membranous glomerulonephritis, neutral endopeptidase deficiency3q26.1-q26.264.56BCHEButyrylcholinesterase1774003q26.2-qter15.50APODApolipoprotein D1077403q278.26AHSGAlpha-2-HS-glycoprotein1386803q281.51SSTSomatostatin1824504p13404.59APBB2Amyloid beta (A4) precursor protein binding, family B, member 26027104p1411.55UCHL1Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)191342Parkinson disease 54p14-p1378.93RFC1Replication factor C (activator 1) 1, 145kDa1025794p16.1550.19SORCS2Sortilin-related VPS10 domain-containing receptor 26062844p16.328.90LRPAP1Low-density lipoprotein receptor-related protein-associated protein 11042254q13.317.16ALBAlbumin103600Analbuminemia, dysalbuminemic hyperthyroxinemia, dysalbuminemic hyperzincemia4q13-q213.21IL8Interleukin 8146930Bronchiolitis4q21114.20SNCASynuclein, alpha (non-A4 component of amyloid precursor)163890Lewy body dementia, Parkinson disease 1, Parkinson disease 44q25491.92COL25A1Collagen, type XXV, alpha 16100044q2514.85CASP6Caspase 6, apoptosis-related cysteine peptidase6015324q2729.00ANXA5Annexin A5131230Recurrent pregnancy loss4q3221.80TLR2Toll-like receptor 2603028Colorectal cancer4q32.19.11LRATLecithin retinol acyltransferase (phosphatidylcholine-retinol O-acyltransferase)604863Leber congenital amaurosis 14, retinal dystrophy, retinitis pigmentosa5p15.352.64SLC6A3Solute carrier family 6 (neurotransmitter transporter, dopamine), member 3126455Epilepsy, parkinsonism-dystonia, attention-deficit hyperactivity disorder, Parkinson disease5q13.186.07PIK3R1Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)171833Agammaglobulinemia 7, insulin resistance5q13.3-q1424.93HMGCR3-hydroxy-3-methylglutaryl-CoA reductase1429105q14.1209.33ARSBArylsulfatase B611542Mucopolysaccharidosis type VI (Maroteaux-Lamy)5q15112.65CASTCalpastatin1140905q21294.01EFNA5Ephrin-A56015355q31105.89FGF1Fibroblast growth factor 1 (acidic)1312205q316.34APBB3Amyloid beta (A4) precursor protein-binding, family B, member 36027115q31.11.97CD14CD14 molecule1581205q31-q322.04ADRB2Adrenoceptor beta 2, surface109690Nocturnal asthma, obesity, diabetes type 25q32491.97PPP2R2BProtein phosphatase 2, regulatory subunit B, beta604325Spinocerebellar ataxia 125q34180.24WWC1WW and C2 domain--containing 16105335q35.317.08DBN1Drebrin 11266606p1216.28VEGFAVascular endothelial growth factor A192240Microvascular complications of diabetes 16p12149.48CD2APCD2-associated protein604241Focal segmental glomerulosclerosis 36p2138.96GLP1RGlucagon-like peptide 1 receptor1380326p21.14.68TREM2Triggering receptor expressed on myeloid cells 2605086Nasu-Hakola disease6p21.37.96HFEHemochromatosis613609Hemochromatosis, microvascular complications of diabetes 7, porphyria cutanea tarda, porphyria variegata6p21.34.31UBDUbiquitin D6060506p21.33.42HLA-AMajor histocompatibility complex, class I, A1428006p21.312.26DDX39BDEAD (Asp-Glu-Ala-Asp) box polypeptide 39B142560Rheumatoid arthritis6p21.32.77TNFTumor necrosis factor191160Asthma, vascular dementia, migraine without aura, insulin resistance, cancer6p21.32.43HSPA1AHeat shock 70kDa protein 1A1405506p21.316.91PPP1R10Protein phosphatase 1, regulatory subunit 106037716p21.33.36AGERAdvanced glycosylation end product-specific receptor600214Diabetes6p21.316.94TAP2Transporter 2, ATP-binding cassette, subfamily B (MDR/TAP)170261Bare lymphocyte syndrome type I due to TAP2 deficiency, Wegener-like granulomatosis, ankylosing spondylitis, insulin-dependent diabetes mellitus, celiac disease6p21.347.89C2Complement component 2613927C2 deficiency6p21.320.62C4BComplement component 4B (Chido blood group)120820C4B deficiency, systemic lupus erythematosus6p21.320.62C4AComplement component 4A (Rodgers blood group)120810C4A deficiency, systemic lupus erythematosus, type I diabetes mellitus6p21.313.05MICBMHC class I polypeptide-related sequence B6024366p21.37.11RXRBRetinoid X receptor, beta1802466p21.3311.72MICAMHC class I polypeptide-related sequence A6001696p22.121.01PGBD1PiggyBac transposable element derived 1N/A6p23462.38ATXN1Ataxin 1601556Spinocerebellar ataxia 16p25.3-p24.3176.61F13A1Coagulation factor XIII, A1 polypeptide134570Factor XIIIA deficiency6p25-p24199.05NEDD9Neural precursor cell expressed, developmentally downregulated 9602265Cancer metastasis6q21213.12FYNFYN oncogene related to SRC, FGR, YES1370256q2149.75SNX3Sorting nexin 36059306q25.1412.78ESR1Estrogen receptor 1133430Breast cancer, atherosclerosis, migraine, myocardial infarction, endometrial cancer, osteoporosis6q25.314.21SOD2Superoxide dismutase 2, mitochondrial147460Microvascular complications of diabetes 6, cardiomyopathy, premature aging, sporadic motor neuron disease, cancer6q2718.54TBPTATA box binding protein600075Spinocerebellar ataxia 17, Parkinson disease7p15.17.68NPYNeuropeptide Y162640Elevated cholesterol levels, higher alcohol consumption, metabolic diseases, cardiovascular diseases7p214.86IL6Interleukin 6 (interferon, beta 2)147620Crohn disease-associated growth failure, diabetes, intracranial hemorrhage in brain cerebrovascular malformations, Kaposi sarcoma, rheumatoid arthritis7p228.92NUDT1Nudix- (nucleoside diphosphate-linked moiety X)-type motif 16003127q11.277.09CD36CD36 molecule (thrombospondin receptor)173510Platelet glycoprotein IV deficiency, macrothrombocytopenia, coronary heart disease7q211440MAGI2Membrane-associated guanylate kinase, WW and PDZ domain-containing 26063827q21.12209.46ABCB1ATP-binding cassette, subfamily B (MDR/TAP), member 1171050Inflammatory bowel disease 137q21.326.22PON1Paraoxonase 1168820Coronary artery disease, coronary artery spasm 2, microvascular complications of diabetes 57q21.336.50PON3Paraoxonase 36027207q21.330.21PON2Paraoxonase 2602447Coronary artery disease, diabetes7q22517.73RELNReelin600514Lissencephaly 2 (Norman-Roberts type)7q22.112.18SERPINE1Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1173360Plasminogen activator inhibitor-1 deficiency, thrombophilia7q31.142.20PPP1R3AProtein phosphatase 1, regulatory subunit 3A600917Insulin resistance7q31.136.40CAV1Caveolin 1, caveolae protein, 22kDa601047Lipodystrophy type 37q31-q3230.06DLDDihydrolipoamide dehydrogenase238331Dihydrolipoamide dehydrogenase deficiency, maple syrup urine disease7q3417.78EPHA1EPH receptor A1179610Cancer7q3623.54NOS3Nitric oxide synthase 3 (endothelial cell)163729Coronary artery spasm 1, hypertension, ischemic stroke, placental abruption7q364.15CDK5Cyclin-dependent kinase 51238317q3659.28PAXIP1PAX-interacting (with transcription, activation domain) protein 16082547q36N/AAD10Alzheimer disease-106096368p11.28.38STARSteroidogenic acute regulatory protein600617Lipoid adrenal hyperplasia8p11.22108.28ADAM9ADAM metallopeptidase domain 9602713Cone-rod dystrophy 98p123.67ADRB3Adrenoceptor beta 3109691Obesity8p1232.96PLATPlasminogen activator, tissue173370Hyperfibrinolysis, thrombophilia8p1229.86EIF4EBP1Eukaryotic translation initiation factor 4E binding protein 16022238p12-q22N/AAD12Alzheimer disease 126110738p21-p1217.90CLUClusterin185430Neoplasms8p229.97NAT2N-acetyltransferase 2 (arylamine N-acetyltransferase)612182Cancer8p2228.19LPLLipoprotein lipase609708Hyperlipidemia, lipoprotein lipase deficiency8p2225.61CTSBCathepsin B116810Esophageal adenocarcinoma, neoplasms8q132.24CRHCorticotropin releasing hormone1225608q2287.63DPYSDihydropyrimidinase613326Dihydropyrimidinuria8q24.181.79ENPP2Ectonucleotide pyrophosphatase/phosphodiesterase 26010609p13.33.05SIGMAR1Sigma nonopioid intracellular receptor 1601978Amyotrophic lateral sclerosis 169p13.316.68VCPValosin-containing protein601023Amyotrophic lateral sclerosis 14 with or without frontotemporal dementia, inclusion body myopathy with early-onset Paget disease and frontotemporal dementia9p2126.74CDKN2ACyclin-dependent kinase inhibitor 2A600160Melanoma and neural system tumor syndrome, orolaryngeal cancer, pancreatic cancer, cutaneous malignant melanoma 29p21.3126.31CDKN2B-AS1CDKN2B antisense RNA 1613149Cardiovascular diseases, cancer, intracranial aneurysm, type-2 diabetes, periodontitis, endometriosis, frailty in the elderly, glaucoma9p2432.69VLDLRVery low-density lipoprotein receptor192977Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 19p24.142.20IL33Interleukin 336086789q13-q21.1244.83APBA1Amyloid beta (A4) precursor protein-binding, family A, member 16024149q21.2294.71PRUNE2Prune homolog 2 (*Drosophila*)6106919q21.2-q21.348.29UBQLN1Ubiquilin 1605046Parkinson disease9q21.33210.79DAPK1Death-associated protein kinase 16008319q21.3374.06GOLM1Golgi membrane protein 16068049q22.1355.04NTRK2Neurotrophic tyrosine kinase, receptor, type 2600456Obesity, mood disorders9q22.1N/AAD11Alzheimer disease 116097909q31.1169.23GRIN3AGlutamate receptor, ionotropic, N-methyl-D-aspartate 3A6066509q31.1147.25ABCA1ATP-binding cassette, subfamily A (ABC1), member 1600046HDL deficiency type 2, Tangier disease, coronary artery disease9q33.113.32TLR4Toll-like receptor 4603030Colorectal cancer, macular degeneration9q33.36.54HSPA5Heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)1381209q3422.98DBHDopamine beta-hydroxylase (dopamine beta-monooxygenase)609312Dopamine beta-hydroxylase deficiency9q3440.10TRAF2TNF receptor-associated factor 26018959q3421.69ABCA2ATP-binding cassette, subfamily A (ABC1), member 26000479q34.3114.12RXRARetinoid X receptor, alpha1802451051.74ENTPD7Ectonucleoside triphosphate diphosphohydrolase 7N/A10p12401.08CACNB2Calcium channel, voltage-dependent, beta 2 subunit600003Brugada syndrome 410p12.31161.34C10orf112Chromosome 10 open reading frame 112N/A10p1338.20OPTNOptineurin602432Amyotrophic lateral sclerosis 12, glaucoma10p13N/AAD7Alzheimer disease 760618710p14-p1327.42PTPLAProtein tyrosine phosphatase-like (proline instead of catalytic arginine), member A61046710p15.235.12PITRM1Pitrilysin metallopeptidase 1N/A10qN/AAD6Alzheimer disease 660552610q11.271.94ALOX5Arachidonate 5-lipoxygenase152390Atherosclerosis, cancer10q11.256.01CHATCholine O-acetyltransferase118490Myasthenic syndrome associated with episodic apnea10q11.23.38DKK1Dickkopf WNT signaling pathway inhibitor 160518910q2114.09TFAMTranscription factor A, mitochondrial60043810q21707.23ANK3Ankyrin 3, node of Ranvier (ankyrin G)60046510q21134.12TET1Tet methylcytosine dioxygenase 160779010q2165.24SGPL1Sphingosine-1-phosphate lyase 160372910q21.116.52CDK1Cyclin-dependent kinase 111694010q21.3175.08LRRTM3Leucine-rich repeat transmembrane neuronal 361086910q21.333.72SIRT1Sirtuin 160447910q22.21780CTNNA3Catenin (cadherin-associated protein), alpha 360766710q22.26.40PLAUPlasminogen activator, urokinase191840Quebec platelet disorder10q22.3768.22KCNMA1Potassium large conductance calcium-activated channel, subfamily M, alpha member 1600150Generalized epilepsy and paroxysmal dyskinesia10q231.38CH25HCholesterol 25-hydroxylase60455110q23.2-q23.338.34LIPALipase A, lysosomal acid, cholesterol esterase613497Cholesteryl ester storage disease, Wolman disease10q23.3105.34PTENPhosphatase and tensin homolog601728Bannayan-Riley-Ruvalcaba syndrome, Cowden syndrome 1, endometrial carcinoma, Lhermitte-Duclos syndrome, macrocephaly/autism syndrome, malignant melanoma, PTEN hamartoma tumor syndrome, squamous cell carcinoma, thyroid carcinoma, VATER association with macrocephaly and ventriculomegaly, glioma, meningioma, prostate cancer10q23.32104.42HECTD2HECT domain-containing E3 ubiquitin protein ligase 2N/A10q23.335.73HHEXHematopoietically expressed homeobox60442010q23-q25122.41IDEInsulin-degrading enzyme146680Type 2 diabetes mellitus10q23-q25624.13SORCS3Sortilin-related VPS10 domain-containing receptor 360628510q23-q25591.05SORCS1Sortilin-related VPS10 domain-containing receptor 160628310q2423.92COX15Cytochrome c oxidase assembly homolog 15 (yeast)603646Cardioencephalomyopathy due to cytochrome c oxidase deficiency 2, Leigh syndrome due to cytochrome c oxidase deficiency10q2469.20ABCC2ATP-binding cassette, subfamily C (CFTR/MRP), member 2601107Dubin-Johnson syndrome10q24.125.25FASFas cell surface death receptor134637Autoimmune lymphoproliferative syndrome type IA, squamous cell carcinoma, autoimmune lymphoproliferative syndrome10q24.2134.34DNMBPDynamin binding protein61128210q24.350.88ALDH18A1Aldehyde dehydrogenase 18 family, member A1138250Cutis laxa type IIIA, hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia, hypoprolinemia, cataracts, connective tissue diseases10q24.37.00CYP17A1Cytochrome P450, family 17, subfamily A, polypeptide 160930017,20-lyase deficiency, 17-alpha-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism, adrenal hyperplasia10q24.3117.82SCDStearoyl-CoA desaturase (delta-9-desaturase)60403110q24.33261.38SH3PXD2ASH3 and PX domains 2AN/A10q24.335.50CALHM1Calcium homeostasis modulator 161223410q25.113.27GSTO1Glutathione S-transferase omega 160548210q25.130.55GSTO2Glutathione S-transferase omega 261231410q25.32.86ADRB1Adrenoceptor beta 1109630Heart failure10q26.3128.60EBF3Early B-cell factor 3607407Glioblastoma multiforme, gastric carcinoma10q26.353.38HTRA1HtrA serine peptidase 1602194CARASIL syndrome, macular degeneration10q26.3374.23ADAM12ADAM metallopeptidase domain 1260271411p11.220.97MAPK8IP1Mitogen-activated protein kinase 8 interacting protein 1604641Noninsulin-dependent diabetes mellitus11p1367.17BDNFBrain-derived neurotrophic factor113505Central hypoventilation syndrome, anorexia nervosa, bulimia nervosa, memory impairment, obsessive-compulsive disorder11p1524.29APBB1Amyloid beta (A4) precursor protein-binding, family B, member 1 (Fe65)60270911p15.13.72SAA1Serum amyloid A1104750Atherosclerosis, rheumatoid arthritis, Crohn's disease, neoplasms11p15.53.40DRD4Dopamine receptor D4126452Autonomic nervous system dysfunction, novelty-seeking personality, attention-deficit hyperactivity disorder11p15.511.24CTSDCathepsin D116840Breast cancer, neuronal ceroid lipofuscinosis type 1011p15.51.43INSInsulin176730Insulin-dependent diabetes mellitus type 2, permanent neonatal diabetes mellitus, diabetes mellitus type 1, familial hyperproinsulinemia with or without diabetes11p15.51.59HBG2Hemoglobin, gamma G142250Transient neonatal cyanosis11q12.113.06MS4A6AMembrane-spanning 4-domains, subfamily A, member 6A60654811q12.241.84MS4A4EMembrane-spanning 4-domains, subfamily A, member 4E60840111q133.06GSTP1Glutathione S-transferase pi 1134660Cancer11q1314.31INPPL1Inositol polyphosphate phosphatase-like 1600829Opsismodysplasia, breast cancer11q13.36.66GALGalanin/GMAP prepropeptide13703511q14112.71PICALMPhosphatidylinositol-binding clathrin assembly protein603025Acute myeloid leukemia, T-cell acute lymphoblastic leukemia, malignant lymphomas11q14.1202.53GAB2GRB2-associated binding protein 260620311q22.2-q22.325.73CASP4Caspase 4, apoptosis-related cysteine peptidase60266411q22.2-q22.320.87IL18Interleukin 18 (interferon-gamma-inducing factor)60095311q22.38.33MMP1Matrix metallopeptidase 1 (interstitial collagenase)120353Epidermolysis bullosa dystrophica, arthritis, chronic obstructive pulmonary disease11q22.37.82MMP3Matrix metallopeptidase 3 (stromelysin 1, progelatinase)185250Coronary heart disease, arthritis11q233.05APOA5Apolipoprotein A-V606368Hyperchylomicronemia, hypertriglyceridemia, hyperlipoproteinemia type V11q232.59APOA4Apolipoprotein A-IV10769011q23.2-q23.330.57BACE1Beta-site APP-cleaving enzyme 160425211q23.2-q24.2181.56SORL1Sortilin-related receptor, L(DLR class) A repeats containing60200511q23.33.16APOC3Apolipoprotein C-III107720Hyperalphalipoproteinemia 2, hypertriglyceridemia11q23-q241.87APOA1Apolipoprotein A-I107680Amyloidosis, combined ApoA-I and apoC-III deficiency, corneal clouding, hypoalphalipoproteinemia, Tangier disease, systemic non-neuropathic amyloidosis11q2474.99APLP2Amyloid beta (A4) precursor-like protein 210477611q2512.32ACAD8Acyl-CoA dehydrogenase family, member 8604773Isobutyryl-CoA dehydrogenase deficiency12p11.23-q13.12N/AAD5Alzheimer disease 560209612p12418.61GRIN2BGlutamate receptor, ionotropic, N-methyl D-aspartate 2B138252Mental retardation12p12.17.11IAPPIslet amyloid polypeptide147940Diabetes type 212p134.55PKP2P1Plakophilin 2 pseudogene 1602861Arrhythmogenic right ventricular dysplasia 912p133.95GAPDHGlyceraldehyde-3-phosphate dehydrogenase13840012p137.18GNB3Guanine nucleotide binding protein (G protein), beta polypeptide 3139130Essential hypertension, obesity12p13.2150.85LRP6Low-density lipoprotein receptor-related protein 6603507Coronary artery disease12p13.2-p12.313.89OLR1Oxidized low density lipoprotein (lectin-like) receptor 1602601Myocardial infarction, atherosclerosis12p13.337.84NCAPD2Non-SMC condensin I complex, subunit D2N/A12p13.3110.31TAPBPLTAP binding protein-like60708112p13.3148.26A2MAlpha-2-macroglobulin103950Alpha-2-macroglobulin deficiency12q12144LRRK2Leucine-rich repeat kinase 2609007Parkinson disease 812q1379.39TFCP2Transcription factor CP218988912q13118.56ATF7Activating transcription factor 760637112q13.1163.49VDRVitamin D (1,25-dihydroxyvitamin D3) receptor601769Involutional osteoporosis12q13.1129.04KANSL2KAT8 regulatory NSL complex subunit 2N/A12q13.1128.54CCNT1Cyclin T1143055Neoplasms12q13.384.86LRP1Low-density lipoprotein receptor-related protein 110777012q1445.33CAND1Cullin-associated and neddylation-dissociated 160772712q23-q24.15.68PLA2G1BPhospholipase A2, group IB (pancreas)17241012q24.1161.42KIAA1033KIAA1033N/A12q24.243.10ALDH2Aldehyde dehydrogenase 2 family (mitochondrial)100650Esophageal cancer alcohol-related12q24.2-q24.31153.66NOS1Nitric oxide synthase 1163731Stroke13q22.118.54KLF5Kruppel-like factor 5 (intestinal)60290313q3425.17DAOAD-amino acid oxidase activator607408Schizophrenia, bipolar affective disorder14q13.18.63PNPPurine nucleoside phosphorylase164050Immunodeficiency due to purine nucleoside phosphorylase deficiency14q21114.25SOS2Son of sevenless homolog 2 (*Drosophila*)60124714q22.1241.61FRMD6FERM domain-containing 661455514q23.2111.52ESR2Estrogen receptor 2 (ER beta)60166314q2471.97MTHFD1Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase172460Abruptio placentae, spina bifida folate-sensitive14q24.387.26PSEN1Presenilin 1104311Familial acne inversa 3, dilated cardiomyopathy 1U, frontotemporal dementia, Pick disease14q24.313.44NPC2Niemann-Pick disease, type C2601015Niemann-Pick disease type C214q24.321.86DLSTDihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)12606314q24.33.46FOSFBJ murine osteosarcoma viral oncogene homolog16481014q24.35.82NGBNeuroglobin60530414q3162.31SEL1LSel-1 suppressor of lin-12-like (*C. elegans*)60232914q3276.35MOKMOK protein kinase60576214q32.113.95SERPINA1Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1107400Emphysema due to AAT deficiency, emphysema-cirrhosis due to AAT deficiency, hemorrhagic diathesis due to antithrombin Pittsburgh, chronic obstructive pulmonary disease14q32.111.68SERPINA3Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3107280Alpha-1-antichymotrypsin deficiency, occlusive cerebrovascular disease14q32.142.88CYP46A1Cytochrome P450, family 46, subfamily A, polypeptide 160408714q32.372.36KLC1Kinesin light chain 160002514q32.3226.40AKT1V-akt murine thymoma viral oncogene homolog 1164730Breast cancer, colorectal cancer, Cowden syndrome 6, ovarian cancer, proteus syndrome, schizophrenia15q11-q12196.68APBA2Amyloid beta (A4) precursor protein-binding, family A, member 260271215q13.132.42CHRFAM7ACHRNA7 (cholinergic receptor, nicotinic, alpha 7, exons 5--10) and FAM7A (family with sequence similarity 7A, exons A--E) fusion60975615q14139.70CHRNA7Cholinergic receptor, nicotinic, alpha 7 (neuronal)118511Schizophrenia, myoclonic epilepsy15q21.1130.54CYP19A1Cytochrome P450, family 19, subfamily A, polypeptide 1107910Aromatase deficiency, aromatase excess syndrome15q21.12.09EID1EP300 interacting inhibitor of differentiation 160589415q21-q23136.90LIPCLipase, hepatic151670Hepatic lipase deficiency, noninsulin-dependent diabetes mellitus15q22153.67ADAM10ADAM metallopeptidase domain 1060219215q22.231.58APH1BAPH1B gamma secretase subunit60763015q22.3148.35SNX1Sorting nexin 160127215q22.33129.34SMAD3SMAD family member 360310915q2428.24CHRNA3Cholinergic receptor, nicotinic, alpha 3 (neuronal)118503Lung cancer15q24.121.11CSKC-src tyrosine kinase12409515q25.163.28IREB2Iron-responsive element binding protein 214758215q26150.50MEF2AMyocyte enhancer factor 2A600660Coronary artery disease 1 with myocardial infarction16p13.317.87UBE2IUbiquitin-conjugating enzyme E2I60166116p13.314.60MEFVMediterranean fever608107Familial Mediterranean fever16q1229.56VPS35Vacuolar protein sorting 35 homolog (*S. cerevisiae*)601501Parkinson disease 1716q2121.92CETPCholesteryl ester transfer protein, plasma118470Hyperalphalipoproteinemia16q2228.10NAE1NEDD8-activating enzyme E1 subunit 160338516q22.117.23NQO1NAD(P)H dehydrogenase, quinone 1125860Tardive dyskinesia, cancer17p11.225.66SREBF1Sterol regulatory element-binding transcription factor 118475617p12139.28COX10Cytochrome c oxidase assembly homolog 10 (yeast)602125Charcot-Marie-Tooth type 1A, hereditary neuropathy with liability to pressure palsies17p1372.14MYH13Myosin, heavy-chain 13, skeletal muscle60348717p13.18.80TNK1Tyrosine kinase, nonreceptor, 160807617p13.119.15TP53Tumor protein p53191170Adrenal cortical carcinoma, breast cancer, choroid plexus papilloma, colorectal cancer, hepatocellular carcinoma, Li-Fraumeni syndrome, nasopharyngeal carcinoma, osteosarcoma, pancreatic cancer, basal-cell carcinoma 7, glioma17p13.131.63MYH8Myosin, heavy-chain 8, skeletal muscle, perinatal160741Carney complex variant, trismus-pseudocamptodactyly syndrome17q2.22PNMTPhenylethanolamine N-methyltransferase171190Essential hypertension17q11.24.17CDK5R1Cyclin-dependent kinase 5, regulatory subunit 1 (p35)60346017q11.243.97BLMHBleomycin hydrolase60240317q11.239.58SLC6A4Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4182138Sudden infant death syndrome, aggressive behavior, depression, obsessive-compulsive disorder17q11.231.68THRAThyroid hormone receptor, alpha190120Hypothyroidism nongoitrous 617q11.20,086MIR144MicroRNA 14461207017q11.2-q1243.76NOS2Nitric oxide synthase 2, inducible163730Hypertension17q11.2-q121.93CCL2Chemokine (C-C motif) ligand 2158105Psoriasis, rheumatoid arthritis, atherosclerosis, spina bifida17q121.91CCL3Chemokine (C-C motif) ligand 3182283Human immunodeficiency virus type 117q21.1133.95MAPTMicrotubule-associated protein tau157140Pick disease, frontotemporal dementia, cortico-basal degeneration, progressive supranuclear palsy, Parkinson disease, tauopathy and respiratory failure17q21.10,445STHSaitohin60706717q21.327.98GRNGranulin138945Frontotemporal lobar degeneration with ubiquitin-positive inclusions, primary progressive aphasia, neuronal ceroid lipofuscinosis 1117q21-q22N/AGPSCGliosis, familial progressive subcorticalN/A17q23.111.08MPOMyeloperoxidase606989Myeloperoxidase deficiency17q23.283.06APPBP2Amyloid beta precursor protein (cytoplasmic tail) binding protein 260532417q23.321.32ACEAngiotensin I converting enzyme (peptidyl-dipeptidase A) 1106180Renal tubular dysgenesis, benign serum increase of angiotensin I-converting enzyme, myocardial infarction, stroke, severe acute respiratory syndrome, microvascular complications of diabetes 317q24.3158.72BPTFBromodomain PHD finger transcription factor60181917q24-q2587.63GRB2Growth factor receptor-bound protein 210835518p11.233.49MC2RMelanocortin 2 receptor (adrenocorticotropic hormone)607397Glucocorticoid deficiency due to ACTH unresponsiveness18q12.133.62DSC1Desmocollin 112564318q12.17.26TTRTransthyretin176300Amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis, carpal tunnel syndrome19p1314.48PIN1Peptidylprolyl *cis*/*trans* isomerase, NIMA-interacting 1601052Cancer19p13.2113.86DNM2Dynamin 2602378Axonal Charcot-Marie-Tooth disease type 2M, Charcot-Marie-Tooth disease type B, centronuclear myopathy19p13.244.47LDLRLow-density lipoprotein receptor606945Familial hypercholesterolemia19p13.2N/AAD9Alzheimer disease 960890719p13.2-p13.141.35NOTCH3Notch 3600276Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy19p13.3-13.242.82C3Complement component 3120700C3 deficiency, atypical hemolytic uremic syndrome, macular degeneration age-related 919p13.327.06GNA11Guanine nucleotide binding protein (G protein), alpha 11 (Gq class)13931319p13.325.47ABCA7ATP-binding cassette, subfamily A (ABC1), member 760541419p13.310.90APBA3Amyloid beta (A4) precursor protein-binding, family A, member 360426219p13.39.29GRIN3BGlutamate receptor, ionotropic, N-methyl-D-aspartate 3B60665119p13.3-p13.2181.75INSRInsulin receptor147670Diabetes mellitus insulin-resistant with acanthosis nigricans, hyperinsulinemic hypoglycemia 5, leprechaunism, Rabson-Mendenhall syndrome19p13.3-p13.215.78ICAM1Intercellular adhesion molecule 114784019q1312.47TOMM40Translocase of outer mitochondrial membrane 40 homolog (yeast)60806119q13.123.02TGFB1Transforming growth factor, beta 1190180Camurati-Engelmann disease19q13.111.30APLP1Amyloid beta (A4) precursor-like protein 110477519q13.1211.91GAPDHSGlyceraldehyde-3-phosphate dehydrogenase, spermatogenic60916919q13.121.41PSENENPresenilin enhancer 2 homolog (*C. elegans*)607632Acne inversa 219q13.243.09PVRL2Poliovirus receptor-related 2 (herpesvirus entry mediator B)600798Multiple sclerosis19q13.23.61APOEApolipoprotein E107741Hyperlipoproteinemia type III, lipoprotein glomerulopathy, sea-blue histiocyte disease, macular degeneration, myocardial infarction19q13.24.69APOC1Apolipoprotein C-I10771019q13.23.26APOC4Apolipoprotein C-IV600745Coronary artery disease19q13.23.58APOC2Apolipoprotein C-II608083Hyperlipoproteinemia type Ib19q13.212.36BCAMBasal cell adhesion molecule (Lutheran blood group)61277319q13.338.76CLPTM1Cleft lip and palate-associated trans-membrane protein 161258519q13.314.94CD33CD33 molecule15959019q13.36.61NR1H2Nuclear receptor subfamily 1, group H, member 260038019q13.354.03MARK4MAP/microtubule affinity-regulating kinase 460649519q13.3221.59EXOC3L2Exocyst complex component 3-like 2N/A19q13.323.06BLOC1S3Biogenesis of lysosomal organelles complex1, subunit 3609762Hermansky-Pudlak syndrome 819q13.3347.86CARD8Caspase recruitment domain family, member 8609051Rheumatoid arthritis19q13.439.76GALPGalanin-like peptide611178Neuroblastic tumor20pN/AAD8Alzheimer disease 860711620p11.214.28CST3Cystatin C604312Cerebral amyloid angiopathy, macular degeneration 1120p1315.44PRNPPrion protein176640Creutzfeldt-Jakob disease, fatal familial insomnia, Gerstmann-Straussler disease, Huntington disease-like 1, kuru, prion disease20pter-p126.55PRNDPrion protein 2 (dublet)60426320q13.2-q13.318.09CHRNA4Cholinergic receptor, nicotinic, alpha 4 (neuronal)118504Nocturnal frontal lobe epilepsy type 120q13.315.38PCK1Phosphoenolpyruvate carboxykinase 1 (soluble)614168Cytosolic phosphoenolpyruvate carboxykinase deficiency21q1198.17SAMSN1SAM domain, SH3 domain, and nuclear localization signals 160797821q21.1134.54TMPRSS15Transmembrane protease, serine 15606635Enterokinase deficiency21q21.1541.88NCAM2Neural cell adhesion molecule 260204021q21.3290.59APPAmyloid beta (A4) precursor protein104760Cerebral amyloid angiopathy21q22.1291.96KCNJ6Potassium inwardly rectifying channel, subfamily J, member 660087721q22.11102.95EVA1CEva-1 homolog C (*C. elegans*)N/A21q22.113.79DNAJC28DnaJ (Hsp40) homolog, subfamily C, member 28N/A21q22.13147.82DYRK1ADual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A600855Down syndrome, mental retardation 721q22.2129.73DOPEY2Dopey family member 260480321q22.3261.50RUNX1Runt-related transcription factor 1151385Acute myeloid leukemia, platelet disorder with associated myeloid malignancy21q22.3108.80BACE2Beta-site APP-cleaving enzyme 2605668Down syndrome21q22.397.56ABCG1ATP-binding cassette, subfamily G (WHITE), member 160307621q22.323.17CBSCystathionine-beta-synthase613381Cystathionine beta-synthase deficiency, homocystinuria, hyperhomocysteinemic thrombosis21q22.350.19MCM3APMinichromosome maintenance complex component 3-associated protein60329421q22.36.50S100BS100 calcium binding protein B176990Down syndrome, epilepsy, amyotrophic lateral sclerosis, melanoma, type I diabetes22q11.2128.24COMTCatechol-O-methyltransferase116790Panic disorder, schizophrenia22q11.2126.88RTN4RReticulon 4 receptor605566Schizophrenia22q11.230.845MIFMacrophage migration inhibitory factor (glycosylation-inhibiting factor)153620Rheumatoid arthritis22q11.238.15GSTT1Glutathione S-transferase theta 1600436Carcinoma22q13.113.15HMOX1Heme oxygenase (decycling) 1141250Heme oxygenase-1 deficiency, chronic obstructive pulmonary disease22q13.221.30SEPT3Septin 360831422q13.3193.16PPARAPeroxisome proliferator-activated receptor alpha170998HyperapobetalipoproteinemiaXp11.23.12HSD17B10Hydroxysteroid (17-beta) dehydrogenase 1030025617-beta-hydroxysteroid dehydrogenase X deficiency, 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency, mental retardationXp11.23115.86MAOBMonoamine oxidase B309860Xp11.391.92MAOAMonoamine oxidase A309850Brunner syndromeXp11.3-p11.234.50TIMP1TIMP metallopeptidase inhibitor 1305370Xp21.168.97OTCOrnithine carbamoyltransferase300461Ornithine transcarbamylase deficiency, Duchenne muscular dystrophyXq12186.59ARAndrogen receptor313700Spinal and bulbar muscular atrophy of Kennedy, prostate cancer, complete androgen insensitivity, hypospadia type 1Xq21.3843.97PCDH11XProtocadherin 11 X-linked300246Xq21.3N/AAD16Alzheimer disease 16300756

Appendix B {#s0215}
==========

Long-Form Names for Genes Listed in [Table 27.2](#t0015){ref-type="table"} **ADH1A**: Alcohol dehydrogenase 1A (class I), alpha polypeptide**AADAC**: Arylacetamide deacetylase**AANAT**: Aralkylamine N-acetyltransferase**ACSL1**: Acyl-CoA synthetase long-chain family member 1**ACSL3**: Acyl-CoA synthetase long-chain family member 3**ACSL4**: Acyl-CoA synthetase long-chain family member 4**ACSM1**: Acyl-CoA synthetase medium-chain family member 1**ACSM2B**: Acyl-CoA synthetase medium-chain family member 2B**ACSM3**: Acyl-CoA synthetase medium-chain family, member 3**ADH1B**: Alcohol dehydrogenase 1B (class I), beta polypeptide**ADH1C**: Alcohol dehydrogenase 1C (class I), gamma polypeptide**ADH4**: Alcohol dehydrogenase 4 (class II), pi polypeptide**ADH5**: Alcohol dehydrogenase 5 (class III), chi polypeptide**ADH6**: Alcohol dehydrogenase 6 (class V)**ADH7**: Alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide**ADHFE1**: Alcohol dehydrogenase, iron containing, 1**AGXT**: Alanine-glyoxylate aminotransferase**AKR1A1**: Aldo-keto reductase family 1, member A1 (aldehyde reductase)**AKR1B1**: Aldo-keto reductase family 1, member B1 (aldose reductase)**AKR1C1**: Aldo-keto reductase family 1, member C1**AKR1D1**: Aldo-keto reductase family 1, member D1**ALDH1A1**: Aldehyde dehydrogenase 1 family, member A1**ALDH1A2**: Aldehyde dehydrogenase family 1, subfamily A2**ALDH1A3**: Aldehyde dehydrogenase family 1, subfamily A3**ALDH1B1**: Aldehyde dehydrogenase 1 family, member B1**ALDH2**: Aldehyde dehydrogenase 2 family (mitochondrial)**ALDH3A1**: Aldehyde dehydrogenase 3 family, member A1**ALDH3A2**: Aldehyde dehydrogenase 3 family, member A2**ALDH3B1**: Aldehyde dehydrogenase 3 family, member B1**ALDH3B2**: Aldehyde dehydrogenase 3 family, member B2**ALDH4A1**: Aldehyde dehydrogenase 4 family, member A1**ALDH5A1**: Aldehyde dehydrogenase 5 family, member A1**ALDH6A1**: Aldehyde dehydrogenase 6 family, member A1**ALDH7A1**: Aldehyde dehydrogenase 7 family, member A1**ALDH8A1**: Aldehyde dehydrogenase 8 family, member A1**ALDH9A1**: Aldehyde dehydrogenase 9 family, member A1**AOX1**: Aldehyde oxidase 1**AS3MT**: Arsenic (+3 oxidation state) methyltransferase**ASMT**: Acetylserotonin O-methyltransferase**BAAT**: Bile acid CoA: amino acid N-acyltransferase (glycine N-choloyltransferase)**CBR1**: Carbonyl reductase 1**CBR3**: Carbonyl reductase 3**CBR4**: Carbonyl reductase 4**CCBL1**: Cysteine conjugate-beta lyase, cytoplasmic**CDA**: Cytidine deaminase**CEL**: Carboxyl ester lipase**CES1**: Carboxylesterase 1**CES1P1**: Carboxylesterase 1 pseudogene 1**CES2**: Carboxylesterase 2**CES3**: Carboxylesterase 3**CES5A**: Carboxylesterase 5A**CHST1**: Carbohydrate (keratan sulfate Gal-6) sulfotransferase 1**CHST2**: Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2**CHST3**: Carbohydrate (chondroitin 6) sulfotransferase 3**CHST4**: Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 4**CHST5**: Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5**CHST6**: Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6**CHST7**: Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7**CHST8**: Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 8**CHST9**: Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9**CHST10**: Carbohydrate sulfotransferase 10**CHST11**: Carbohydrate (chondroitin 4) sulfotransferase 11**CHST12**: Carbohydrate (chondroitin 4) sulfotransferase 12**CHST13**: Carbohydrate (chondroitin 4) sulfotransferase 13**COMT**: Catechol-O-methyltransferase**CYB5R3**: Cytochrome b5 reductase 3**CYP1A1**: Cytochrome P450, family 1, subfamily A, polypeptide 1**CYP1A2**: Cytochrome P450, family 1, subfamily A, polypeptide 2**CYP1B1**: Cytochrome P450, family 1, subfamily B, polypeptide 1**CYP2A6**: Cytochrome P450, family 2, subfamily A, polypeptide 6**CYP2A7**: Cytochrome P450, family 2, subfamily A, polypeptide 7**CYP2A13**: Cytochrome P450, family 2, subfamily A, polypeptide 13**CYP2B6**: Cytochrome P450, family 2, subfamily B, polypeptide 6**CYP2C8**: Cytochrome P450, family 2, subfamily C, polypeptide 8**CYP2C9**: Cytochrome P450, family 2, subfamily C, polypeptide 9**CYP2C18**: Cytochrome P450, family 2, subfamily C, polypeptide 18**CYP2C19**: Cytochrome P450, family 2, subfamily C, polypeptide 19**CYP2D6**: Cytochrome P450, family 2, subfamily D, polypeptide 6**CYP2D7P1**: Cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 1**CYP2E1**: Cytochrome P450, family 2, subfamily E, polypeptide 1**CYP2F1**: Cytochrome P450, family 2, subfamily F, polypeptide 1**CYP2J2**: Cytochrome P450, family 2, subfamily J, polypeptide 2**CYP2R1**: Cytochrome P450, family 2, subfamily R, polypeptide 1**CYP2S1**: Cytochrome P450, family 2, subfamily S, polypeptide 1**CYP2W1**: Cytochrome P450, family 2, subfamily W, polypeptide 1**CYP3A4**: Cytochrome P450, family 3, subfamily A, polypeptide 4**CYP3A5**: Cytochrome P450, family 3, subfamily A, polypeptide 5**CYP3A7**: Cytochrome P450, family 3, subfamily A, polypeptide 7**CYP3A43**: Cytochrome P450, family 3, subfamily A, polypeptide 43**CYP4A11**: Cytochrome P450, family 4, subfamily A, polypeptide 11**CYP4A22**: Cytochrome P450, family 4, subfamily A, polypeptide 22**CYP4B1**: Cytochrome P450, family 4, subfamily B, polypeptide 1**CYP4F2**: Cytochrome P450, family 4, subfamily F, polypeptide 2**CYP4F3**: Cytochrome P450, family 4, subfamily F, polypeptide 3**CYP4F8**: Cytochrome P450, family 4, subfamily F, polypeptide 8**CYP4F11**: Cytochrome P450, family 4, subfamily F, polypeptide 11**CYP4F12**: Cytochrome P450, family 4, subfamily F, polypeptide 12**CYP4Z1**: Cytochrome P450, family 4, subfamily Z, polypeptide 1**CYP7A1**: Cytochrome P450, family 7, subfamily A, polypeptide 1**CYP7B1**: Cytochrome P450, family 7, subfamily B, polypeptide 1**CYP8B1**: Cytochrome P450, family 8, subfamily B, polypeptide 1**CYP11A1**: Cytochrome P450, family 11, subfamily A, polypeptide 1**CYP11B1**: Cytochrome P450, family 11, subfamily B, polypeptide 1**CYP11B2**: Cytochrome P450, family 11, subfamily B, polypeptide 2**CYP17A1**: Cytochrome P450, family 17, subfamily A, polypeptide 1**CYP19A1**: Cytochrome P450, family 19, subfamily A, polypeptide 1**CYP20A1**: Cytochrome P450, family 20, subfamily A, polypeptide 1**CYP21A2**: Cytochrome P450, family 21, subfamily A, polypeptide 2**CYP24A1**: Cytochrome P450, family 24, subfamily A, polypeptide 1**CYP26A1**: Cytochrome P450, family 26, subfamily A, polypeptide 1**CYP26B1**: Cytochrome P450, family 26, subfamily B, polypeptide 1**CYP26C1**: Cytochrome P450, family 26, subfamily C, polypeptide 1**CYP27A1**: Cytochrome P450, family 27, subfamily A, polypeptide 1**CYP27B1**: Cytochrome P450, family 27, subfamily B, polypeptide 1**CYP39A1**: Cytochrome P450, family 39, subfamily A, polypeptide 1**CYP46A1**: Cytochrome P450, family 46, subfamily A, polypeptide 1**CYP51A1**: Cytochrome P450, family 51, subfamily A, polypeptide 1**DDOST**: Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit (non-catalytic)**DHRS1**: Dehydrogenase/reductase (SDR family) member 1**DHRS2**: Dehydrogenase/reductase (SDR family) member 2**DHRS3**: Dehydrogenase/reductase (SDR family) member 3**DHRS4**: Dehydrogenase/reductase (SDR family) member 4**DHRS7**: Dehydrogenase/reductase (SDR family) member 7**DHRS9**: Dehydrogenase/reductase (SDR family) member 9**DHRS12**: Dehydrogenase/reductase (SDR family) member 12**DHRS13**: Dehydrogenase/reductase (SDR family) member 13**DHRSX**: Dehydrogenase/reductase (SDR family) X-linked**DPEP1**: Dipeptidase 1 (renal)**DPYD**: Dihydropyrimidine dehydrogenase**EPHX1**: Epoxide hydrolase 1, microsomal (xenobiotic)**EPHX2**: Epoxide hydrolase 2, microsomal (xenobiotic)**ESD**: Esterase D**FMO1**: Flavin containing monooxygenase 1**FMO2**: Flavin containing monooxygenase 2**FMO3**: Flavin containing monooxygenase 3**FMO4**: Flavin containing monooxygenase 4**FMO5**: Flavin containing monooxygenase 5**FMO6P**: Flavin containing monooxygenase 6 pseudogene**GAL3ST1**: Galactose-3-O-sulfotransferase 1**GAMT**: Guanidinoacetate N-methyltransferase**GLRX**: Glutaredoxin (thioltransferase)**GLYAT**: Glycine-N-acyltransferase**GNMT**: Glycine N-methyltransferase**GPX1**: Glutathione peroxidase 1**GPX2**: Glutathione peroxidase 2 (gastrointestinal)**GPX3**: Glutathione peroxidase 3 (plasma)**GPX4**: Glutathione peroxidase 4**GPX5**: Glutathione peroxidase 5**GPX6**: Glutathione peroxidase 6 (olfactory)**GPX7**: Glutathione peroxidase 7**GSR**: Glutathione reductase**GSTA1**: Glutathione S-transferase alpha 1**GSTA2**: Glutathione S-transferase alpha 2**GSTA3**: Glutathione S-transferase alpha 3**GSTA4**: Glutathione S-transferase alpha 4**GSTA5**: Glutathione S-transferase alpha 5**GSTCD**: Glutathione S-transferase, C-terminaldomain containing**GSTK1**: Glutathione S-transferase kappa 1**GSTM1**: Glutathione S-transferase mu 1**GSTM2**: Glutathione S-transferase mu 2 (muscle)**GSTM3**: Glutathione S-transferase mu 3 (brain)**GSTM4**: Glutathione S-transferase mu 4**GSTM5**: Glutathione S-transferase mu 5**GSTO1**: Glutathione S-transferase omega 1**GSTO2**: Glutathione S-transferase omega 2**GSTP1**: Glutathione S-transferase pi 1**GSTT1**: Glutathione S-transferase theta 1**GSTT2**: Glutathione S-transferase theta 2**GSTZ1**: Glutathione S-transferase zeta 1**GZMA**: Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)**GZMB**: Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)**HNMT**: Histamine N-methyltransferase**HSD11B1**: Hydroxysteroid (11-beta) dehydrogenase 1**HSD17B10**: Hydroxysteroid (17-beta) dehydrogenase 10**HSD17B11**: Hydroxysteroid (17-beta) dehydrogenase 11**HSD17B14**: Hydroxysteroid (17-beta) dehydrogenase 14**INMT**: Indolethylamine N-methyltransferase**MAOA**: Monoamine oxidase A**MAOB**: monoamine oxidase B**METAP1**: Methionyl aminopeptidase 1**MGST1**: Microsomal glutathione S-transferase 1**MGST2**: Microsomal glutathione S-transferase 1**MGST3**: Microsomal glutathione S-transferase 3**NAA20**: N(alpha)-acetyltransferase 20, NatB catalytic subunit**NAT1**: N-acetyltransferase 1 (arylamine N-acetyltransferase)**NAT2**: N-acetyltransferase 2 (arylamine N-acetyltransferase)**NNMT**: Nicotinamide N-methyltransferase**NQO1**: NAD(P)H dehydrogenase, quinone 1**NQO2**: NAD(P)H dehydrogenase, quinone 2**PNMT**: Phenylethanolamine N-methyltransferase**PON1**: Paraoxonase 1**PON2**: Paraoxonase 2**PON3**: Paraoxonase 3**POR**: P450 (cytochrome) oxidoreductase**PTGES**: Prostaglandin E synthase**PTGS1**: Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)**PTGS2**: Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)**SAT1**: Spermidine/spermine N1-acetyltransferase 1**SMOX**: Spermine oxidase**SOD1**: Superoxide dismutase 1, soluble**SOD2**: Superoxide dismutase 2, mitochondrial**SULT1A1**: Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1**SULT1A2**: Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2**SULT1A3**: Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 3**SULT1B1**: Sulfotransferase family, cytosolic, 1B, member 1**SULT1C1**: Sulfotransferase family, cytosolic, 1C, member 1**SULT1C2**: Sulfotransferase family, cytosolic, 1C, member 2**SULT1C3**: Sulfotransferase family, cytosolic, 1C, member 3**SULT1C4**: Sulfotransferase family, cytosolic, 1C, member 4**SULT1E1**: Sulfotransferase family 1E, estrogen-preferring, member 1**SULT2A1**: Sulfotransferase family, cytosolic, 2A,dehydroepiandrosterone (DHEA)-preferring, member 1**SULT2B1**: Sulfotransferase family, cytosolic, 2B, member 1**SULT4A1**: Sulfotransferase family 4A, member 1**SULT6B1**: sulfotransferase family, cytosolic, 6B, member 1**TBXAS1**: Thromboxane A synthase 1 (platelet)**TPMT**: Thiopurine S-methyltransferase**TST**: Thiopurine S-methyltransferase**UCHL1**: Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)**UCHL3**: Ubiquitin carboxyl-terminal esterase L3 (ubiquitin thiolesterase)**UGT1A1**: UDP glucuronosyltransferase 1 family, polypeptide A1**UGT1A3**: UDP glucuronosyltransferase 1 family, polypeptide A3**UGT1A4**: UDP glucuronosyltransferase 1 family, polypeptide A4**UGT1A5**: UDP glucuronosyltransferase 1 family, polypeptide A5**UGT1A6**: UDP glucuronosyltransferase 1 family, polypeptide A6**UGT1A7**: UDP glucuronosyltransferase 1 family, polypeptide A7**UGT1A8**: UDP glucuronosyltransferase 1 family, polypeptide A8**UGT1A9**: UDP glucuronosyltransferase 1 family, polypeptide A9**UGT1A10**: UDP glucuronosyltransferase 1 family, polypeptide A10**UGT2A1**: UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus**UGT2A3**: UDP glucuronosyltransferase 2 family, polypeptide A3**UGT2B10**: UDP glucuronosyltransferase 2 family, polypeptide B10**UGT2B11**: UDP glucuronosyltransferase 2 family, polypeptide B11**UGT2B15**: UDP glucuronosyltransferase 2 family, polypeptide B15**UGT2B17**: UDP glucuronosyltransferase 2 family, polypeptide B17**UGT2B28**: UDP glucuronosyltransferase 2 family, polypeptide B28**UGT2B4**: UDP glucuronosyltransferase 2 family, polypeptide B4**UGT2B7**: UDP glucuronosyltransferase 2 family, polypeptide B7**UGT3A1**: UDP glycosyltransferase 3 family, polypeptide A1**UGT8**: UDP glycosyltransferase 8**XDH**: Xanthine dehydrogenase

[^1]: **Note:** See Appendix B for long-form names of genes listed.
